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MANAGING HIV TREATMENT IN RESOURCE-LIMITED AND
DYNAMIC ENVIRONMENTS
Amin Khademi, PhD
University of Pittsburgh, 2013
Containing the HIV epidemic is one of the most pressing global health care issues. An-
tiretroviral therapy, the only treatment option for chronic HIV, inhibits the progression of
the disease. However, there is a severe shortage of treatment in the developing world, particu-
larly in Sub-Saharan Africa, the area hit the hardest by the epidemic. The current guidelines
recommend treating HIV patients until death, known as a nonabandonment policy. HIV-
infected patients develop resistant mutations and they benefit marginally from treatment.
Therefore, there is an opportunity cost for treating patients until they die. We estimate
the price of nonabandonment policies in HIV treatment where resources are limited. We
develop a mathematical framework to optimize the allocation of scarce HIV treatment for
a broad class of admissible policies. Pursuant to this goal, we develop a Markov model of
the progression of a population of susceptible and infected individuals. Then, we restrict
our attention to two classes of admissible policies: (i) nonabandonment policies, and (ii)
abandonment-permitted policies. The price of nonabandonment policies is estimated by the
difference between the optimal solution of these two classes of admissible policies. Since the
state spaces of the models are unbounded, solving the allocation problems is intractable.
Therefore, we approximate the price of nonabandonment policies by the difference between
a lower bound on the best performance of allocation policies in abandonment-permitted set-
tings and an upper bound of that in nonabandonment settings. We show that the price of
following the nonabandonment policies in HIV treatment is as much as 41%. Moreover, they
shed light on the key role allocation policies play in containing the epidemic. In resource-
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rich environments, when to start HIV treatment is a fundamental question. Current models
do not consider the rate of new antiretroviral development in their analysis. We model
the arrival of HIV pipeline drugs in resource-rich environments as a split Poisson process
and incorporate it in a validated simulation model to measure the effect of HIV pipeline
drugs on HIV treatment. The model with the inclusion of pipeline drugs recommends earlier
treatment.
Keywords: HIV, Resource-Limited Settings, Nonabandonment, Approximate Dynamic Pro-
gramming, Split Poisson Process, Pipeline Drugs.
iv
TABLE OF CONTENTS
PREFACE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ix
1.0 INTRODUCTION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
2.0 LITERATURE REVIEW . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5
2.1 Clinical Studies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5
2.2 Mathematical and Simulation Models . . . . . . . . . . . . . . . . . . . . . . 6
2.3 Overview of Individual HIV Simulation Model . . . . . . . . . . . . . . . . . 8
3.0 A SIMULATION MODEL OF HIV TREATMENT IN RESOURCE-
LIMITED SETTINGS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10
3.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10
3.2 Simulation Model . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11
3.2.1 Overview of Population HIV Model . . . . . . . . . . . . . . . . . . . 11
3.2.2 Definition of Coverage . . . . . . . . . . . . . . . . . . . . . . . . . . . 12
3.3 A Queueing Model . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
3.4 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17
3.5 Large-Scale HIV Simulation Model . . . . . . . . . . . . . . . . . . . . . . . 22
3.6 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23
4.0 TIME TO ABANDONNONABANDONMENT? HIV IN SUB-SAHARAN
AFRICA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26
4.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26
4.2 Modeling the Price of Nonabandonment Policies . . . . . . . . . . . . . . . . 27
4.2.1 Optimal Allocation of Scarce HIV Treatment . . . . . . . . . . . . . . 27
4.2.2 Price of Nonabandonment . . . . . . . . . . . . . . . . . . . . . . . . 32
v
4.3 Approximate Solutions and Performance Guarantee . . . . . . . . . . . . . . 33
4.3.1 Lower Bound . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33
4.3.2 Upper Bound . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39
4.4 Numerical Study . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42
4.4.1 Computational Issues . . . . . . . . . . . . . . . . . . . . . . . . . . . 42
4.4.2 Benchmark Policies . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44
4.4.3 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45
4.5 Case Study: HIV Simulation in Sub-Saharan Africa . . . . . . . . . . . . . . 47
4.5.1 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47
4.5.2 Policy Insights . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47
4.6 HIV Transmission Dynamics Formulation . . . . . . . . . . . . . . . . . . . 49
4.7 Sampling Constraints . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52
4.8 Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53
5.0 THE EFFECT OF PIPELINE DRUGS ON HIV TREATMENT . . . . 55
5.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 55
5.2 Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 56
5.2.1 Analyzing Inter-Arrival Time of Pipeline Drugs . . . . . . . . . . . . . 57
5.2.2 Cross-Resistance . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 57
5.2.3 Efficacy and Toxicity of New Antiretroviral Agents . . . . . . . . . . . 59
5.2.4 Scenarios Regarding When to Initiate ART . . . . . . . . . . . . . . . 59
5.2.5 Scenarios Regarding Sensitivity Analysis . . . . . . . . . . . . . . . . 60
5.3 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 60
5.3.1 Probability Distributions . . . . . . . . . . . . . . . . . . . . . . . . . 60
5.3.2 Sensitivity Analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . 64
5.4 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 66
6.0 CONCLUSIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 69
BIBLIOGRAPHY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 72
vi
LIST OF TABLES
1 Results for population size, prevalence-based, and cumulative incidence-based
coverage . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18
2 Assigning treatment according to a priority list . . . . . . . . . . . . . . . . . 36
3 Nonabandonment ADP policies performance compared to WHO recommenda-
tions (%) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45
4 Abandonment-permitted ADP policies performance compared to WHO rec-
ommendations (%) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46
5 Price of nonabandonment policies (%) . . . . . . . . . . . . . . . . . . . . . . 46
6 Performance of policies compared to nonabandonment policy (%) . . . . . . . 47
7 Risk and health priorities in ADP assignment . . . . . . . . . . . . . . . . . . 48
8 Aggregated priorities for health and risk under the ADP policy . . . . . . . . 49
9 Validity of exponential inter-arrival time distributions . . . . . . . . . . . . . 62
10 Approval date of ARV classes . . . . . . . . . . . . . . . . . . . . . . . . . . . 62
11 The cross-resistance probability distributions . . . . . . . . . . . . . . . . . . 62
12 The probability distribution of the number of drugs resistant to a mutation . 63
13 Life-years and QALYs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 64
14 Relative life-years and QALYs gain due to pipeline (%) . . . . . . . . . . . . 65
15 The optimal CD4 count for initiating the therapy with and without pipeline . 66
16 Sensitivity analysis for 30 year old patients . . . . . . . . . . . . . . . . . . . 66
17 Sensitivity analysis for 40 year old patients . . . . . . . . . . . . . . . . . . . 66
18 Sensitivity analysis for 50 year old patients . . . . . . . . . . . . . . . . . . . 67
vii
LIST OF FIGURES
1 Prevalence-based and cumulative incidence-based coverage . . . . . . . . . . . 13
2 Population size and different coverage definitions . . . . . . . . . . . . . . . . 19
3 Results of the simulation for prevalence-based and cumulative incidence-based
coverage . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20
4 Comparing the results of the queueing model with simulation . . . . . . . . . 21
5 Large-scale HIV simulation calibration . . . . . . . . . . . . . . . . . . . . . . 23
6 Schematic view of the procedure for finding the upper bound . . . . . . . . . 40
7 Comparing approximated and simulated value function . . . . . . . . . . . . 44
8 Comparison of treatment time under WHO and ADP policies . . . . . . . . . 50
9 The arrival process of HIV pipeline drugs . . . . . . . . . . . . . . . . . . . . 58
10 Quantile-Quantile plot for the goodness of fit for the arrival process . . . . . 61
viii
PREFACE
To Fattaneh and Yadollah
ix
1.0 INTRODUCTION
The human immunodeficiency virus (HIV) is a retrovirus that causes acquired immunod-
eficiency syndrome (AIDS), a condition that progressively reduces the effectiveness of the
immune system. HIV/AIDS has infected 34 million people worldwide and killed over 20 mil-
lion since 1989 [WHO, 2010]. In 2010, 2.7 million people became infected with HIV and 1.8
million people died of AIDS-related causes [Joint United Nations Programme on HIV/AIDS,
2010].
CD4 cells, a type of white blood cell, protect the human body from infection. HIV at-
tacks CD4 cells and kills them. As CD4 cells become depleted, HIV patients become more
vulnerable to infectious diseases, resulting in AIDS and eventually death [Stine, 2003]. An-
tiretroviral therapy (ART), the only treatment option for chronic HIV infection, is capable
of effectively regulating the progression of the virus. The first ART, known as AZT, was
introduced in 1986 [Shernoff and Smith, 2001]. Due to developing resistant mutations, the
effect of AZT on patients’ health becomes limited [Shernoff and Smith, 2001]. Therefore,
by developing new drugs, treatment of HIV has changed to highly active antiretroviral ther-
apy (HAART). HAART involves taking a combination of antiretroviral (ARV) drugs which
usually entails three drugs from various classes [United States Department of Health and
Services, 2004]. HAART has significantly decreased the HIV mortality rate, and the status
of HIV has been transformed from a fatal disease to a chronic one [Palella Jr. et al., 1998].
While treatment options are largely available in the developed world, access to ART
remains one of the biggest public health problems in the developing world, where demand
for treatment largely exceeds its supply [WHO, 2010]. For instance, in Sub-Saharan Africa,
more than 22 million people are infected and coverage1 in this area ranges from 23% in Niger
1Coverage is defined as the number of patients treated divided by the total number of patients.
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to 83% in Botswana, with the majority of countries having coverage less than 40% [Joint
United Nations Programme on HIV/AIDS, 2010]. As a result, in 2010, ten million patients in
need of treatment did not receive it [Joint United Nations Programme on HIV/AIDS, 2010].
While the number of ART doses available to patients has steadily risen over the course of
the last 20 years, the number of HIV cases has also continued to increase [WHO, 2010].
Looking ahead, current funding for HIV international programs is well below the funding
level required to contain the epidemic: while the latter is expected to grow by $2 billion
in 2015, the former, currently $3-4 billion below current needs, remains virtually constant
[UNAIDS, 2012].
The focus of this dissertation is on two problems in HIV treatment. In Chapter 3,
we develop a simulation model to investigate the social effects of ART on containing the
HIV epidemic in resource-limited settings. The HIV progression of an infected individual
in the population is governed by a validated microsimulation model. To capture limited
resources, we consider a limited number of treatment doses. Treatment increases the size
of the infected population because treated patients live much longer than untreated ones.
We investigate the effect of treatment on the population size at different coverage levels.
We also show that the current definition of coverage by WHO falls short of fully describing
the effects of HIV treatment on the population. We provide a new definition for coverage
that describes the effect of ART on population size more precisely. We show that current
published coverage data, which indicates that the HIV epidemic in Africa is nearly half-way
to being fully treated, does not consider the dynamic effects of coverage on the size of the
infected population.
International guidelines recommend treating HIV-infected patients until they die, known
as nonabandonment policies. HIV-infected patients develop resistant mutations to treatment
and marginally benefit from it. Following a nonabandonment strategy hinders policy mak-
ers from reallocating available treatment doses to other patients who might benefit more.
Therefore, the whole population is affected by an opportunity cost by keeping patients on
treatment until death. In Chapter 4, we introduce a mathematical model to quantify the price
of nonabandonment policies in HIV treatment when resources are limited. First, we propose
a mathematical framework for optimizing the allocation of scarce HIV treatment doses in a
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heterogeneous population for a broad class of admissible policies. Then, we restrict our atten-
tion to two classes of nonabandonment and abandonment-permitted admissible policies. We
define the price of nonabandonment as the difference between the solutions of abandonment-
permitted and nonabandonment. Due to an unbounded state space, solving these problems
is intractable. Therefore, we estimate a lower bound on price by the difference between a
lower bound on improvement for the abandonment-permitted setting and an upper bound on
improvement in the nonabandonment setting. We use the linear programming approach to
approximate dynamic programming (ADP) to find efficient solutions and derive structural
properties of the proposed policies. Moreover, by providing upper bounds, we show that
the policies produced by our approximation method are close to optimal. In particular, the
price of nonabandonment is as much as 41% of the total discounted life expectancy of the
whole population. We use clinically validated HIV progression and transmission models to
calibrate our model and evaluate the performance of policies produced by approximate dy-
namic programming. We compare these policies against the recommendations of the World
Health Organization (WHO). Our results indicate that the proposed policies outperform
WHO recommendations in terms of total discounted quality-adjusted life-years (QALYs) of
the population by as much as 8%. Moreover, they shed light on the key role allocation
policies play in containing the epidemic.
Additionally, the question of when to initiate HIV treatment in resource-rich environ-
ments has received significant attention. On one hand, early treatment reduces the viral load
in early stages of infection and, therefore, decreases the likelihood of irreparable damage to
the immune system. On the other hand, early treatment increases the likelihood of devel-
oping resistant mutations and adverse effects of HIV treatment due to toxicity. All of the
available models consider a fixed number of HIV therapies in analyzing the optimal time to
initiate HIV treatment. In Chapter 5, we investigate the effect of the rate of new antiretrovi-
ral drug development on HIV treatment and in particular, on the optimal time to initiate the
therapy. We model the arrival of pipeline drugs as a split Poisson process and incorporate
it into the previously validated simulation model. Including pipeline drugs in the model
supports early treatment in almost all cases. In addition, the predicted life expectancy gains
with the presence of pipeline drugs range from almost nothing to 8%, depending upon the
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age of patients, viral load, and the CD4 count at which therapy is initiated. Our results show
that the most important factor in increasing the quality-adjusted life-years due to pipeline
drugs is reducing the toxicity.
We discuss conclusions, limitations, and future extensions of the dissertation in Chapter
6.
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2.0 LITERATURE REVIEW
Because the literature on HIV is extremely broad, we focus only on the literature that is
related to this dissertation. First, we provide a brief medical literature review on treatment
initiation times in resource-rich settings. Next, we provide a brief literature review on math-
ematical and simulation models used for analyzing when to start treatment, analyzing HIV
transmission dynamics, and analyzing the effect of treatment on transmission. Finally, we
describe an overview of the HIV simulation model used in to develop our simulation models.
2.1 CLINICAL STUDIES
Since the discovery of HIV, researchers have debated when patients should initiate therapy
[Lepri et al., 2001]. After an initial phase, where early initiation was recommended, it
soon became apparent that early initiation resulted in a multitude of side effects and early
acquisition of resistant mutations [Sulkowski et al., 2000]. In this regard, Phillips et al. [2003]
recommend late treatment initiation so as to balance the trade-off between immune system
recovery and the cumulative effect of drug toxicity. Sterling et al. [2003] show that patients
who wait for starting treatment until their CD4 count drops below 350 cells/mm3 have the
longest survival. Siegfried et al. [2010] report the results of many randomized controlled
trials that consider the optimal time to initiate HIV treatment. Lawn et al. [2011] have a
literature review of clinical trials for the optimal time to initiate HIV therapy in patients
with HIV-associated opportunistic infections.
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2.2 MATHEMATICAL AND SIMULATION MODELS
Researchers have used mathematical models to determine the optimal time to initiate HIV
treatment. Badri et al. [2006] consider a Markov state-transition model to estimate the life
expectancy and the treatment cost for several treatment initiation policies. Braithwaite et al.
[2008] develop a simulation model to investigate the optimal threshold for HIV treatment
initiation. Shechter et al. [2008] model the problem of when to initiate therapy as an optimal
stopping problem using Markov decision processes.
The availability of different ART regimes1 in resource-rich environments has brought
attention to the issue of ART sequencing and optimization. In this context, Wein et al.
[1997] cast optimal individual ART treatment using control theory. There, a decision maker
attempts to control a patient’s viral load2 (VL) by suggesting dynamic therapies; see, for
example, Kirschner et al. [1997], Brandt and Chen [2001], and Jeffrey et al. [2003] for similar
approaches. To the best of our knowledge, all of these studies deal with the issue of ART
for a single patient and implicitly assume drugs are available to patients whenever they wish
to initiate or switch treatment regimens. In our study, drug availability is restricted and, to
some extent, endogenously determined, as is treatment initiation.
In addition to the “when to start treatment” problem, many researchers have tried to
investigate the effect of treatment on HIV transmission. In particular, societal approaches to
treatment allocation have received significant attention in recent decades, mostly from the
clinical literature. Central to such an approach is a model of transmission dynamics, which
plays a major role in the study of the evolution and control of related sexually transmitted
diseases (STDs); see, for example, Mollison [1995], Anderson and May [1991], Watts and
May [1992], and Kretzschmar and Morris [1996]. Our modeling effort follows closely that of
Garnett and Anderson [1994] who model the sexual behavior of a population via a system of
differential equations. As in our model, they consider different risk groups, shaped according
to their sexual behavior, and an exogenous mixing pattern in the population.
1The ART regimen is a combination of antiretroviral medications.
2Viral load estimates the amount of virus in a mL of blood.
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ART effect on the progression of the HIV epidemic remains unclear; see, for example,
Wagner et al. [2010], and Velasco-Hernandez et al. [2002]. In this regard, the work of Bag-
galey et al. [2005] constitutes a first step in clarifying this issue. They review mathematical
models which discuss the effect of HIV treatment in resource-limited settings. Blower et al.
[2003] use a mathematical model to predict the effect of low or moderate rate of ART usage
on HIV prevalence and incidence in the developing world. Granich et al. [2009] develop a
mathematical model to predict the effect of widespread use of ART and especially “screen
and treat” strategy on the HIV epidemic. They show that by implementing the screen and
treat strategy HIV will be eliminated in 50 years. However, Wagner et al. [2010] argue
that the model used in Granich et al. [2009] does not consider the development of resistant
mutations and does not consider the effect of ART on the population size.
It is worth noting that none of the studies above consider the effect of allocation policies
on the HIV epidemic. An exception is the work by Walensky et al. [2009], who study
HIV treatment in resource-limited settings. They explore the effect of different initiation
policies on the life expectancy and the cost of treatment of patients at an individual level.
Their results suggest the earlier treatment is more cost-effective, however, they do not model
the drug scarcity constraints explicitly, and instead use a decision tree to predict patients’
survival, conditioned on the results of a large control trial.
Zaric and Brandeau [2001] consider the problem of allocating resources to a limited
number of interventions, such as needle exchange programs and condom use, to improve
QALYs and the number of HIV infections averted. However, their model does not consider
ART, a key HIV intervention. Restricting attention to a limited set of allocation policies,
the authors show that the efficiency of a policy depends on factors such as incidence and
prevalence, and which interventions are considered. Long et al. [2006] explore an epidemic
model of HIV in a population of injection drug users (IDUs) and non-IDUs. They investigate
the cost-effectiveness of ART in the population.
There has been recent interest in applying ADP to health care problems. Maxwell et al.
[2009] model the problem of efficient ambulance redeployment and use simulation to tune the
parameters of their value function approximation. Patrick et al. [2008] explore a dynamic
multi-priority scheduling model for patients in a diagnostic facility. They use the linear
7
programming approach to ADP to minimize patient waiting time. Erdelyi and Topaloglu
[2009] study a similar problem using ADP in policy space by parameterizing protection-level
based policies. Lee et al. [2008] examine the problem of optimal timing and management of
dialysis therapy. They develop an ADP algorithm to maximize a patient’s welfare and use
a simulation model to derive near-optimal strategies. Our work uses ADP methods to craft
efficient treatment allocation policies.
Computing upper bounds in stochastic dynamic programming is a vexing problem.
Brown et al. [2010] provide a technique to compute an upper bound for a finite-horizon
stochastic dynamic program by relaxing information and using duality. For using this ap-
proach one needs to generate sample paths of the original problem, find a good penalty
function, and solve the deterministic dynamic program. However, in our model in Chapter
4, generating a sample path for the whole population for a finite horizon is burdensome.
Moreover, solving the deterministic dynamic program is extremely challenging since there is
exponential number of ways to allocate treatment at each step. In addition, the quality of
upper bounds depends on the choice of the penalty function. We provide two techniques to
compute upper bounds to guarantee the quality of our approximations.
2.3 OVERVIEW OF INDIVIDUAL HIV SIMULATION MODEL
The HIV simulation model in Chapter 3 is based on an individual microsimulation model
that replicates the probabilistic progression of the disease in a patient over time [Braithwaite
et al., 2011]. The model tracks the health of a patient on a daily basis: viral load updates
consider the history of resistant mutation and compliance, and CD4 count updates consider
several factors such as VL, treatment status, and age; it also replicates the progression of
resistant mutation biologically. The development, mechanics, and validation of this model
have been previously described [Braithwaite et al., 2006, 2007]. The simulation model com-
putes HIV-mortality rates based on health and age of a patient, and non HIV-mortality rates
based on age and the drugs’ toxicity and side effects.
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The model, originally calibrated and validated on data in the US, has demonstrated
the ability to predict time to treatment failure [Braithwaite et al., 2005], the development
of resistant mutations [Braithwaite et al., 2006], survival, and change in CD4 count and
viral load over time [Braithwaite et al., 2008], both with and without treatment. Recently,
a version of the model calibrated with data from western Kenya has been used to test
alternative thresholds for treatment initiation and the effect of adherence on the quality-
adjusted life-years for patients in Sub-Saharan Africa [Braithwaite et al., 2011]. We extend
this version of the model to conduct our dynamic simulations.
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3.0 A SIMULATION MODEL OF HIV TREATMENT IN
RESOURCE-LIMITED SETTINGS
3.1 INTRODUCTION
The development of highly active antiretroviral therapy has revolutionized the treatment of
HIV disease, producing dramatic increases in survival [Palella et al., 2003]. However, the
benefits of these therapies have not been fully realized in many resource-limited environ-
ments. The lack of sufficient treatment has been especially severe in Sub-Saharan Africa,
where many countries are able to provide HIV treatment to only a small portion of the pop-
ulation infected with HIV. The screen and treat strategy recommends treating HIV-infected
individuals regardless of their CD4 count [Wagner et al., 2010]. Researchers disagree about
implementing the screen and treat strategy, especially in resource-limited settings. For in-
stance, Granich et al. [2009] show that the HIV epidemic can be eliminated by using the
screen and treat strategy and recommend widespread use of this strategy. However, this
model does not consider the effect of developing resistant mutations and the effect of ART
in increasing the life expectancy of HIV-infected patients. Moreover, there is a debate about
whether the screen and treat strategy is implementable in resource-limited settings [Dodd
et al., 2010].
Over the past decade, cooperation between developed nations, the pharmaceutical in-
dustry, the World Health Organization and many private charities has resulted in a dramatic
increase in the resources available to resource-limited nations to treat HIV disease. A com-
mon measure of the success of these efforts is the increase in “coverage”; the proportion
of HIV-infected population meeting criteria for treatment who are being treated. In 2010,
the coverage levels in most Sub-Saharan African countries was less than 40%, leaving large
10
portions of the population untreated. However, in just a few years, international efforts have
increased coverage rates substantially. In Sub-Saharan Africa, the average coverage level has
increased form 3% in 2003 to 49% in 2012 [WHO, 2012].
One direct consequence of expanded access to treatment is a growth in the size of the HIV-
infected population who qualify for treatment. Because patients on therapy live substantially
longer than patients without therapy [Palella Jr. et al., 1998], treatment will increase the
size of the HIV-infected population who qualify for treatment, and therefore increase the
resources required to fully treat that population. The purpose of this chapter is to estimate
the impact of various levels of treatment coverage on the resulting size of the HIV-infected
population who qualify for treatment.
3.2 SIMULATION MODEL
We adapted an existing, validated individual simulation model of HIV, calibrated on data
from Sub-Saharan Africa [Braithwaite et al., 2011] that predicts the progression of HIV
on and off treatment to represent a dynamic population of HIV-infected patients under
various assumptions regarding the number of doses of antiretroviral therapy available. The
population is dynamic in that we represent new infections being added to the cohort at a
constant rate. To illustrate the problem, we consider the situation in which only a single
ARV regimen is available and analyze the relationship between the resources available for
HIV treatment and the resulting size of the stable HIV-infected population. This assumption
is quite mild in this setting because second line and third line therapies are much more
expensive and their efficacy is not significantly higher [Pujades-Rodriguez et al., 2008].
3.2.1 Overview of Population HIV Model
We extend the Braithwaite et al. [2011] individual HIV model by running multiple unique
copies of the model simultaneously to represent a cohort of patients and to simulate the
effect of different levels of scarce ART doses. We create an initially stable HIV-infected
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population of an arbitrary size, setting the new HIV-infection rate equal to the death rate
of the HIV-infected population in the absence of treatment. When patients are treated, the
population size grows over time because treated patients live longer than untreated patients,
resulting in a death rate lower than the new HIV infection rate. The population continues
to rise until the number of deaths once again equals the new infection rate, at which time
a new stable population size is reached. We identify the effect of treatment on the stable
population size, and estimate the resource required (as represented by the number of doses
of ART) to treat the entire population.
We assume that in the beginning of the simulation there is a set number of doses of
first line ARV available. As there are insufficient doses to treat everyone, the model chooses
which patients to start on therapy using the World Health Organization recommendations for
resource-limited settings, which prioritizes therapy initiation for the sickest patients (patients
with the lowest CD4 count), and keeps patients on treatment until they die [WHO, 2012].
That is, a dose of ART becomes available only when a patient on therapy dies.
3.2.2 Definition of Coverage
The size of the HIV-infected population will change over time depending on the amount of
ART available. When not everyone in the population can be treated, some HIV-infected
patients will acquire HIV disease, become ill and die without receiving ART. Therefore, we
define two coverage concepts: (i) prevalence-based coverage, which refers to the number of
doses divided by the HIV-infected population at a given time; and (ii) cumulative incidence-
based coverage, which refers to the number of patients who receive treatment at some point
during their life. One might interpret the prevalence-based coverage as the perceived cover-
age and the cumulative incidence-based coverage as effective coverage.
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Example 1 We illustrate these definitions and their differences by means of a simple exam-
ple: suppose that
• untreated patients live exactly 2 years;
• treated patients live exactly 14 years;
• only 1 ARV dose is available;
• the new HIV infection rate is equal to the death rate from HIV disease (a new case
develops every 2 years).
Figure 1 illustrates this scenario: at any given time, prevalence-based coverage is 50% as
one half of the current HIV-infected population is being treated, but over a 14-year period
only one of a total of eight HIV-infected individuals receives treatment for a cumulative
incidence-based coverage of 12.5%.
The common interpretation of coverage (which we call prevalence-based coverage), is a “snap-
shot” measure, and overestimates the number of HIV-infected individuals who receive treat-
ment, as at most levels of coverage, many eligible HIV-infected patients will acquire HIV,
live through their progressive disease and die prior to receiving ART. We consider an initial
Figure 1: Prevalence-based and cumulative incidence-based coverage
population of 10,000 HIV-infected patients and vary the number of doses available from zero
until everyone who qualifies for coverage is able to receive treatment. After an increase in
the number of ART doses available, the HIV-infected population rises, and stabilizes at a
higher steady state. The warm-up period takes around 20 years, after which the infected
population size stabilizes. Simulations are run for 300 years after reaching steady state to
provide stable estimates of the prevalence-based and cumulative incidence-based coverage,
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and the population size at that number of available doses. In addition, we relate the stable
population size and cumulative incidence-based coverage to the portion of people currently
living at various levels of prevalence-based coverage in Sub-Saharan Africa.
3.3 A QUEUEING MODEL
We use queueing theory to model the population of HIV-infected patients and derive expres-
sions for the prevalence-based and cumulative incidence-based coverage, as well as the stable
population size.
We consider a queueing system in which customers arrive from an infinite pool of pop-
ulation and d servers are available. An arriving customer is served immediately if there is
a free server, and joins a single queue otherwise. We assume that the service times of cus-
tomers are independent and have distribution G, and the arrival process of customers has
inter-arrival distribution F . In our setting, patients are customers and treatment doses are
servers. Because patients may die while waiting for treatment, we have a G/G/d queueing
system with reneging.
Suppose that we have a population of N0 infected patients. In the base case, the expected
number of patients who enter the system is equal to the expected number of patients who
die. Note that we do not consider the physiological characteristics of infected individuals.
In particular, we assume that the probability of death for a patient is independent of her
health when she is waiting for treatment in the queue and when she has started treatment.
Let Pn denote the n
th patient, and this patient enters the system at time tn. The point
process {tn : n ≥ 1} is assumed to be an increasing sequence of nonnegative numbers with
the counting process {N(t) : t ≥ 0}. By this we have N(t) = max{n : tn ≤ t}, where
N(t) shows the total number of patients who have entered the system by time t. Let Wn
be the life-years of patient Pn after arriving to the system and t
d
n be the time when the
patient dies. We have tdn = tn +Wn. The departure process
{
Nd(t) : t ≥ 0} is the counting
process for death times
{
tdn
}
, i.e., Nd(t) shows the number of patients who died by time t.
Note that almost surely Nd(t) ≤ N(t) , t ≥ 0. A patient is alive at time t if and only if
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tn ≤ t < tdn = tn +Wn. Let L(t) be the total number of patients in the population at time
t. We have
L(t) =
∞∑
n=1
I
{
tn ≤ t < tdn
}
=
∑
n:tn≤t
I {Wn > t− tn}
=
N(t)∑
n=1
I {Wn > t− tn} ,
where I {.} is the indicator function. Let λ be the arrival rate to the system, ω be the
average life-years, and ` be the time average number of patients. We have
λ := lim
t→∞
N(t)
t
,
ω := lim
n→∞
1
n
n∑
j=1
Wj,
` := lim
t→∞
1
t
∫ t
0
L(s) ds.
Because the system is stable and non-preemptive, the relation between the time average
number of patients in the population with the average life-years of a patient can be formalized
in the following theorem which is the Little’s law [Little, 1961].
Theorem 1 (Little’s law) If both λ and ω exist and are finite, then ` exists and ` = λω.
In our problem, we are interested in making the infected population size stable at L0 in the
absence of treatment, where L0 is the expected number of patients in the system. Therefore,
the arrival rate should be λ0 =
L0
ω0
, where ω0 is the average life-years of an untreated patient.
The conventional way of thinking about coverage may be misleading in this scenario.
Because one might think that starting from a population of L0 patients, one needs L0 treat-
ment doses to reach the coverage level of 100%. We show that the amount of treatment
doses needed to treat the entire population is much larger than L0.
Let l(d) be the expected population size by introducing d treatment doses. We would
like to compute the asymptotic behavior of l(d), that is,
L = lim
d→∞
l(d).
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We know that in this scenario all patients receive treatment. Therefore, by Little’s law we
have
L = λ0ω1,
where ω1 is the expected life-years of a treated patient. By substituting λ0 =
L0
ω0
we have
L = L0
ω1
ω0
.
Since ω1
ω0
≥ 1, the expected number of treatment doses needed to treat every patient in the
population is greater than or equal to L0. In Section 3.4, we show that the expected number
of treatment doses needed to treat every patient is almost seven times that of the initial
number of patients in the population.
Now we derive a formulation for the cumulative incidence-based coverage defined in
Section 3.2.2. Let NT (t) be the total number of patients who received treatment somehow
in their lifetime up to time t, CIBC denote the cumulative incidence-based coverage, and
PBC denote the prevalence-based coverage. Define
CIBC = lim
t→∞
NT (t)
Nd(t)
.
The following proposition relates the conventional prevalence-based coverage with the cu-
mulative incidence-based coverage.
Proposition 1 Let µ and ω be the average treatment time and lifetime of a patient, respec-
tively. Then we have
CIBC = PBC × ω
µ
. (3.1)
Proof: Because a G/G/d queueing system with reneging reaches steady state [Koole and
Mandelbaum, 2002], we have a constant rate for birth and treatment. Let ρb, and ρt be the
birth rate and treatment rate, respectively. In the steady state, we have
CIBC = lim
t→∞
ρt × t
ρb × t =
ρt
ρb
.
Also, for the birth rate and treatment rate we have
ρb =
l(d)
ω
, ρt =
d
µ
.
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Therefore, the relation between cumulative incidence-based coverage and prevalence-based
coverage can be described as
CIBC =
ρt
ρb
=
d
µ
l(d)
ω
=
d
l(d)
× ω
µ
= PBC × ω
µ
.
¤
Since ω
µ
≤ 1, cumulative incidence-based coverage is always less than or equal to the
prevalence-based coverage. Therefore, the conventional way of thinking about coverage al-
ways underestimates the amount of resources needed to reach a particular coverage level.
3.4 RESULTS
The steady state HIV-infected population size grows by a factor of 7 (from an initial size
of 10,000 to nearly 70,000), relative to a setting where treatment is not available (Figure
2). Above 70,000 doses, all patients who develop HIV disease can be treated, and the fully
treated death rate will once again equal the rate of HIV acquisition.
Figure 2 also illustrates the relationship between prevalence-based and cumulative incidence-
based coverage and the size of the HIV-infected population: prevalence-based coverage always
exceeds cumulative incidence-based coverage, and underestimates the proportion of patients
being treated by as much as 29%. The relationship between coverage and the number of
doses is nonlinear: with an initial population of 10,000 HIV-infected individuals, 20,000 doses
will stabilize at a cumulative incidence-based coverage of approximately 50%, but adding an
additional 20,000 doses will only increase cumulative incidence-based coverage to about 80%.
Figure 3 illustrates more directly the relationship between prevalence-based and cumu-
lative incidence-based coverage, the number of doses required to achieve that coverage, and
the current context of coverage rates in Sub-Saharan Africa. There is a significant increase
in the stable population size from prevalence-based coverage at or below 50% to prevalence-
based coverage above 50%. For example, the stable population size when prevalence-based
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Table 1: Results for population size, prevalence-based, and cumulative incidence-based cov-
erage
Number of doses Population size Prevalence-based coverage Cumulative incidence-based coverage
0 10000 0 0
5000 14902 0.335526 0.108451
10000 19370.3 0.516254 0.226165
15000 23829.6 0.629469 0.341727
20000 28343.7 0.705625 0.460432
25000 32982.6 0.757974 0.548502
30000 37689.8 0.795971 0.627019
35000 42383.8 0.825788 0.701543
40000 47094.4 0.849358 0.77054
45000 51415.2 0.875228 0.822499
50000 55434.1 0.901973 0.85998
55000 59356.4 0.926607 0.896152
60000 63248.9 0.948633 0.933286
65000 66794.5 0.973134 0.965079
70000 69132.1 1.01255 0.998069
coverage in 50% is approximately 20,000, but the population will rise to nearly 70,000 with
sufficient doses to treat all HIV-infected patients who need therapy. Because the population
size increases, and because treated patients live longer than those not on therapy, this pop-
ulation increase will require an even more dramatic increase in the number of ART doses.
From Figure 3, at 10,000 doses the prevalence-based coverage is just over 50%, but it re-
quires nearly seven times that number to fully cover the population. In Sub-Saharan Africa,
nearly 90% of the HIV-infected population live in areas below 60% prevalence-based cover-
age, implying that the resources required to fully cover the currently infected population in
Sub-Saharan Africa is substantially larger than the amount of resources dedicated to this
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Figure 2: Population size and different coverage definitions
effort and predicted by World Health Organization and other international organizations and
charities. This is a direct consequence of increasing the life expectancy due to treatment for
HIV patients.
In the end, we compare the results of the simulation model with the queueing model.
According to the queueing model, the total population in 100% coverage is equal to the
total population with no treatment multiplied by ω1
ω0
. The results of running the individual
simulation model show that a patient in absence of treatment lives 2.2 years on average, and
a patient with treatment lives 15.1 years on average. Therefore, the total population size
with 100% coverage should be 15.1
2.2
= 6.86 times of the initial population size. Now we would
like to see if there is a significant difference between the result of the simulation model and
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Figure 3: Results of the simulation for prevalence-based and cumulative incidence-based
coverage
the queueing model. Since we have 30 samples from the simulation model, we assume that
they have a normal distribution and they are independent. At the 0.05 level we fail to reject
the null hypothesis, i.e, H0 : µ = 6.86 (p-value=0.17). Therefore, there is no statistically
significant difference between the results of the simulation model and the queueing model.
We also test the results of the simulation for cumulative incidence-based coverage with
equation (3.1). Pursuant to this goal, we consider an initial population of 100 patients and
introduce treatment doses in different levels. We simulate the system and compute the cu-
mulative incidence-based coverage, the average life-years of a patient in each treatment level,
and the average treatment time.
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We use equation (3.1) to compute the cumulative incidence-based coverage. Figure 4
compares the result of the simulation model with equation (3.1). As can be seen in Figure
4, the queueing model can predict the cumulative incidence-based coverage generated by the
simulation model very well.
Figure 4: Comparing the results of the queueing model with simulation
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3.5 LARGE-SCALE HIV SIMULATION MODEL
The large-scale HIV simulation model extends the simulation model described in Section
3.2 by incorporating transmission dynamics, following the model in Garnett and Anderson
[1994] (see Section 4.6 for details of the transmission model). Using the original model’s
flexibility in accommodating different treatment policies, we can replicate resource-limited
conditions and simulate a broad variety of allocation policies.
For parameter calibration we use data from HIV literature in Sub-Saharan Africa. In
particular, we use the estimates in Fraser et al. [2007] to compute the probability of trans-
mission per sexual encounter. In addition, following Cohen and Gay [2010], we assume that
patients on ART are 70% less likely to transmit the disease. The probabilities in Ciaranello
et al. [2008] are used for mother-to-child transmission.
The transition probability from childhood to adulthood is such that the expected child-
hood period is 15 years (individuals older than 15 years are sexually active [UNAIDS, 2010]).
We set the initial number of children to be 40% of the population (as almost 40% of the pop-
ulation are children in Sub-Saharan Africa [CIA, 2010]). Along with Garnett and Anderson
[1996], we use four risk groups for adults. In our model, it is assumed that 89% of adults
establish one partner while 11% have multiple partners (11% of couples are polygamous in
Kenya [Bellan et al., 2013]). For polygamous individuals, we consider 3,5, and 7 partners and
the distribution over them is 3:2:1, respectively. Since there is no available data on change
of individual’s sexual behavior in Sub-Saharan Africa, we assume that adults do not change
their risk category. The probability of death for susceptible individuals is such that their
expected lifetime equals the life expectancy at birth in Sub-Saharan Africa [World Bank,
2010].
For calibrating the model, we compare the simulation results for prevalence of HIV with
the actual prevalence in Kenya from 1990 to 2000. HIV interventions such as condom use,
education, and ART were insufficiently available in Kenya during that period, and the actual
progression of the disease can be observed in an intervention-free population [UNAIDS,
2010]. After the year 2000, several interventions have been implemented concurrently in
Kenya; therefore, data for the marginal effect of one intervention (treatment in our case) on
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prevalence is not available. Figure 5 shows the results of the simulation model in the absence
of treatment and the actual HIV prevalence in Kenya when no intervention was available.
As can be seen, the simulation model results almost match the actual data.
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Figure 5: Large-scale HIV simulation calibration
3.6 DISCUSSION
Coverage is not static: it varies through time and depends on the effectiveness of the alloca-
tion policy in place, as this impacts the stable population size of HIV-infected individuals.
Also, the traditional cross-sectional definition of coverage, which we term “prevalence-based
coverage” fails to capture the impact that different levels of resources have on the stable
HIV-infected population sizes, and may substantially underestimate the resources required
to fully cover a population.
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Therefore, an analysis based on the traditional, cross-sectional, static, or prevalence-
based concept of coverage might fail to quantify the magnitude of the efforts required to
treat the HIV epidemic. Our analysis shows that increasing the coverage level in Sub-
Saharan Africa (currently about 50%, on average) is likely to require substantially more
resources than implied by current prevalence-based coverage levels. Doubling the current
resources available will come nowhere near fully treating the epidemic. We introduce the
concept of cumulative incidence-based coverage, the portion of HIV-infected patients who
receive treatment at some point in their lifetime, is a more accurate and useful measure of
the progress made in HIV care.
This work has several strengths and weaknesses. Our simulation model is calibrated using
data from east Africa. The single patient simulation model has demonstrated its ability to
predict outcomes in Sub-Saharan Africa. It accurately replicates the progression of the
disease in each treatment scenario, and reports prevalence-based and cumulative incidence-
based coverage, and the number of doses of ART required to treat a population of a given
size. However, the analysis in this work considers only a single ARV regimen, ignoring
the effect of the second and third treatment regimens. However, including multiple ART
regimens would only compound the problem: second and third line therapies are much
more expensive than first line, and patients in the simulation would live even longer in the
presence of multiple treatment options. The model does not take into account any impact
on the epidemic itself. Although future work will incorporate this aspect, it is difficult to
estimate the expected direction of the effect. Increasing treatment decreases the viral load
of treated individuals, which decreases the likelihood of transmission. However, treatment
also dramatically increases the size of the HIV-infected population, and although treated,
nevertheless increases the potential pool of patients who may transmit the infection.
We ignore many capabilities of the underlying HIV model in these simulations. For
example, a portion of patients will discontinue their HIV medication because of side effects
and toxicity: we assume all treated individuals in the model remain on treatment until
death. We re-estimate the results of the model allowing adherence to fall to levels seen
in Sub-Saharan Africa and prevalence-based and cumulative incidence-based coverage are
slightly less discordant but the overall effect persists.
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The increases in treatment of HIV disease is Sub-Saharan Africa has been a massive in-
ternational effort, requiring the cooperation and dedication of individual health ministries in
Africa, multiple charitable foundations, the WHO, many developed nations and the pharma-
ceutical industry. The results of this research indicate that current published coverage data
that indicates that the HIV epidemic in Africa is nearly half-way to being fully treated does
not take into account the dynamic effects of coverage on the size of the infected population.
25
4.0 TIME TO ABANDON NONABANDONMENT? HIV IN
SUB-SAHARAN AFRICA
4.1 INTRODUCTION
The current strategy to allocate limited HIV therapies is to assign the available treatment
dose to the sickest patients in the population and treat them until they die [WHO, 2012].
Most policy makers follow this nonabandonment strategy because removing a patient from
treatment is considered by some to be unethical. Due to resistance, HIV drugs become
less effective and the patient becomes sicker; however, under nonabandonment policies, a
drug regimen may not be reallocated to another patient who might receive more benefit.
Therefore, in resource-limited settings, the nonabandonment policy may be suboptimal.
For instance, if a policy maker removes a patient who has developed resistant mutations
and is marginally benefiting from treatment, he may be able to assign the treatment dose
to another patient who needs it more. In doing so, the health of the patient who starts
treatment improves, and he is less likely to transmit the disease. Note that the health of the
patient whose treatment is abandoned declines. However, the overall benefit of removing the
patient for the society increases.
In this chapter, we quantify the price of nonabandonment policies for HIV treatment
in resource-limited settings. We develop a mathematical framework to optimize treatment
allocation under resource constraints for a broad class of admissible policies. To quantify
the price of nonabandonment, we restrict our attention to two classes of admissible policies:
(i) nonabandonment policies, and (ii) abandonment-permitted policies. These allocation
problems are intractable because the state spaces of their respective Markov decision process
(MDP) formulations are unbounded. We estimate a lower bound on the price as the difference
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between the lower bound on the best performance in the abandonment-permitted setting
and an upper bound of the best performance in the nonabandonment setting. To solve our
problems, we use the linear programming approach to approximate dynamic programming
to derive efficient allocation policies. We also provide two techniques to compute the upper
bound and guarantee the performance of the proposed policies. We demonstrate that the
price of following the nonabandonment strategy in HIV treatment in resource-limited settings
is as much as 41% of the total discounted quality-adjusted life expectancy of the population.
In addition, we use the large-scale simulation model of Chapter 3 to compare the performance
of the proposed policies against relevant benchmarks based on milder assumptions than those
required by the MDP model. Finally, we provide insights on the way that our policies assign
treatment to patients and reallocate treatment. In particular, we investigate when the ADP
policies remove patients from treatment. To the best of our knowledge, this is the first
study that incorporates both progression and transmission of HIV for finding near-optimal
treatment allocation policies, while considering the population as a whole.
4.2 MODELING THE PRICE OF NONABANDONMENT POLICIES
In this section, we establish a modeling framework for quantifying the performance of dif-
ferent allocation policies through the use of Markov decision processes. Then, we define the
price of nonabandonment policies as the gap in performance between the best policies within
two classes of admissible policies.
4.2.1 Optimal Allocation of Scarce HIV Treatment
We consider a Markovian discrete-time infinite-horizon model of the progression of an HIV
epidemic within a population of heterogeneous individuals. At a broad level, the population
is composed of susceptible individuals and infected patients.
Model primitives and assumptions. Susceptible individuals are characterized by a risk
index r which categorizes their level of sexual activity, and evolves stochastically in time.
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Note that concurrent sexual partnerships is the key driver in the HIV epidemic in Sub-
Saharan Africa [Eaton et al., 2011]. Note that children have their own risk index and are
assumed to be sexually inactive. We let R denote the set of risk categories which we assume is
finite. With respect to treatment, for now we let P denote the finite set of possible treatment
phases an infected patient may be on at any time. We index treatment phases by p. We
assume that patients can start treatment at most once. In Section 4.2.2, we provide precise
definitions of this set for different classes of admissible policies.
In addition to their risk, infected patients are also characterized by a health index. For
patients who are not on treatment, the health index represents their current CD4 count.1
Our model discretizes the range of CD4 counts, which is in line with clinical practice [WHO,
2012]. The health index for patients exposed to treatment is represented by a vector with
three elements: (i) their CD4 count at the beginning of treatment, (ii) their maximum CD4
count while on treatment, and (iii) their current CD4 count. This choice allows us to model
the development of virus mutations resistant to treatment. Note that the development of
resistant mutations is not observable in practice, and needs to be inferred from CD4 count
evolution. We let H be the finite set of health indices (we assume that susceptible individuals
always have the best possible health condition).
Let X tr be the total number of susceptible individuals in risk group r at time t, and Y
t
i,p
that of infected individuals in infected state i ∈ I and treatment phase p, where I := R×H.
With this, we let St := (X t, Y t) denote the state of the population at time period t, where
X t = (X tr : r ∈ R), and Y t = (Y ti,p : i ∈ I, p ∈ P ), and let S denote the state space (note
that S is unbounded), i.e.,
S :=
{
S = (X, Y ) ∈ Z+|R| × Z+|I||P |
}
.
We assume that each patient undergoing treatment consumes one dose per period, and let
K denote the number of treatment doses available per period, which we assume is constant.
In our model, actions move patients from one treatment phase to another, e.g., from pre-
treatment to the first phase of being on treatment. We let A(S) denote the set of actions
1CD4 count is a measurement of the strength of the immune system and is used as a health indicator in
practice.
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available to policy makers in state S ∈ S, and S(a) denote the state of the system after taking
an action a. In Section 4.2.2, we explain in detail two sets of admissible actions for the class
of policies of interest. In particular, we explain actions sets for the abandonment-permitted
and nonabandonment scenarios.
Transition dynamics. We assume that the risk of a susceptible individual changes from
r to r′ with probability ηr,r′ , independent of everything. To model the transition from
childhood to adulthood, we let ηr be the probability of a child’s transition to risk group r
at each period. We let ρp,p
′
i,i′ (a) denote the probability that a patient in treatment phase p,
with risk r and health h evolves to treatment phase p′ with risk r′ and health h′ after action
a is taken. We also let pr(S, a) denote the probability that a susceptible individual in risk
category r becomes infected within a decision epoch when the state of the system is S and
action a is taken. Following Garnett and Anderson [1994], our model approximates2 pr(S, a)
by
pr(S, a) ≈ µr
∑
r∈R
ωr,r′
∑
h∈H
∑
p∈P νr′,h,p Yr′,h,p(a)
Nr′(S)
, (4.1)
where µr is the average number of partners a susceptible individual in risk group r es-
tablishes, (ωr,r′ : (r, r
′) ∈ R2) represents elements of a mixing matrix describing partnership
patterns within the population, νr′,h,p represents the probability of disease transmission in
a partnership with an infected patient of risk group r′, health state h, and treatment phase
p, and Nr′(S) denotes the total population of individuals in risk group r
′. Further details
about the transmission model can be found in Section 4.6, where we provide error bounds
for our approximation and show that the maximum error bound is relatively small.
At each period, each adult individual gives birth to a child with probability γr. We
capture mother-to-child transmission by letting κi,p be the probability that a child born to
an infected patient is also infected. Similarly, we assume that each susceptible and infected
individual dies within a decision epoch with probabilities dr, and di,p, respectively. With
this notation we have that
X t+1r = X
t
r +Br −DEr − TRr; Y t+1i,p = Y ti,p + EVi,p −DEi,p,
2We assume that each susceptible individual becomes infected in different partnerships independent of
each other.
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where Br denotes total number of children who become adults of risk group r, DEr denotes
total number of susceptible individuals in risk group r who die, TRr denotes total number
of susceptible individuals in risk group r who become infected, EVi,p denotes total number
of individuals who evolve to infected state i and treatment phase p, and DEi,p denotes total
number of patients who die in a period in infected state i and treatment phase p.
Markov decision process formulation. We consider a policy maker who seeks to maxi-
mize the expected discounted cumulative quality-adjusted life years3 of the population (rel-
ative to susceptible individuals). Let g(S, a) denote the immediate reward resulting from
applying action a ∈ A(S) in state S ∈ S. That is,
g(S, a) :=
∑
r∈R
Xr +
∑
i∈I
∑
p∈P
ui,pYi,p(a), a ∈ A(S) , S ∈ S,
where ui,p ∈ (0, 1] denotes the quality of life experienced by a patient in infected state i
and treatment phase p. Let Jpi(S) denote the expected discounted cumulative QALYs of the
population when S0 = S under policy pi ∈ Π, where Π is the set of stationary allocation
policies. That is,
Jpi(S) := E
{ ∞∑
t=0
λt g(St, pi(S))|S0 = S
}
, S ∈ S,
where pi(S) denotes the action selected by an admissible policy pi in state S, and λ ∈ (0, 1) is
a discount factor. Policy makers seek to maximize Jpi(S) by solving V (S) := suppi {Jpi(S)}.
To ensure the value function V is well defined we assume that rewards are discounted at a
rate larger than that of the population growth, as formalized in Assumption 1, which we
assume holds throughout the chapter. Note that this assumption is not restrictive. We use
real data in our model and the amount of λ should be less than 0.96.
3This factor reflects the fact that the quality of life of patients in poor health states or undergoing
treatment (and its side effects) is lower than that of healthy untreated patients: see Glasziou et al. [1990].
30
Assumption 1 The discount factor λ is such that
1− λ
λ
>
∑
r 6=0
γr −min {di,p, dr : i ∈ I , p ∈ P} .
For any real-valued function J : S → R (note that the domain is the state space), define the
following per-capita supremum norm
‖J‖pc := sup
{ |J(S)|
|S|+ 1 : S ∈ S
}
.
The next result extends MDP classical results to characterize the optimal value function and
the optimal policy (see Puterman [1994]).
Lemma 1 There exists v > 0 and V such that ‖V ‖pc < v and V is the unique solution to
J(S) = max
a∈A(S)
{
g(S, a) + λ Ea
{
J(S1)|S0 = S}} , S ∈ S, (4.2)
such that ‖J‖pc <∞. In addition, there exits an optimal stationary policy pi, where
pi(S) ∈ argmax
a∈A(S)
{
g(S, a) + λ Ea
{
V (S1)|S0 = S}} , S ∈ S.
Proof: Define δ := λ
(∑
r 6=0 γr −min(i,p),r {di,p, dr}
)
. Assumption 1 states that δ ∈ [0, 1).
Note that g(S, a) ≤ |S|+ 1 for all S ∈ S, and that
λ Ea
{
(
∣∣S1∣∣+ 1)|S0 = S} ≤ δ(|S|+ 1), a ∈ A(S), S ∈ S.
This implies that
V (S) ≤ (1− δ)−1(|S|+ 1), S ∈ S,
and therefore ‖V ‖pc ≤ v, where v := (1− δ)−1 [Puterman, 1994, Proposition 6.10.1, p.234].
Moreover, (4.2) has a unique solution J such that ‖J‖pc <∞, and that pi is indeed optimal
[Puterman, 1994, Theorem 6.10.4, p.236]. We conclude that V satisfies the Bellman equations
(4.2). ¤
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4.2.2 Price of Nonabandonment
In this section, we consider two sets of admissible policies to quantify the price of nona-
bandonment policies in HIV treatment. First is the set of nonabandonment policies, where
policy makers treat patients until death. We assume that only one line of treatment is
available (this is a mild assumption since second line therapies are much more expensive
than the first line therapy [Pujades-Rodriguez et al., 2008]). Thus, patients are either on
treatment or not. The second set of admissible policies, known as abandonment-permitted
policies, include those where policy makers are able to remove patients from treatment. We
restrict our attention to policies that remove patients from treatment at most once. In this
setting, patients might be in one of three treatment phases: (i) pre-treatment phase, (ii) on-
treatment phase, and (iii) post-treatment phase. Note that patients in the post-treatment
phase are not allowed to start treatment. For the purpose of our formulation, we consider
P = {0, 1, 2}, where p = 0 denotes the pre-treatment phase, p = 1 denotes the on-treatment
phase, and p = 2 denotes the post-treatment phase.
Define the action space A(S) as
A(S) :=
{
ai,p :
∑
i∈I
(ai,1 − ai,2 + Yi,1) ≤ K , 0 ≤ ai,p ≤ Yi,p−1, i ∈ I, p ∈ P
}
, S ∈ S,
where ai,1 represents the number of patients in infected state i moved to treatment, ai,2
represents the number of patients in infected state i removed from treatment, and ai,0 = 0.
Note that we do not impose a course of treatment in our model, but rather let the model
decide when the patient should be removed from treatment, if ever (see Section 4.5.2).
The set of admissible policies for the nonabandonment case is represented by Π = {pi :
pi(S) ∈ A(S); ai,2 = 0}, where Yi,p(a) = Yi,p + ai,p. For the abandonment-permitted case
the set of admissible policies is represented by Π = {pi : pi(S) ∈ A(S)}, where Yi,p(a) =
Yi,p + ai,p − ai,p+1. The price of nonabandonment (PoN) can be expressed as
PoN = max
pi∈Π
Jpi(S)−max
pi∈Π
Jpi(S). (4.3)
PoN measures the benefit that the society might obtain in terms of total discounted quality
of life by allowing policy makers to remove patients from treatment. We interpret it as
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the price that society pays by following the nonabandonment policy, where policy makers
keep patients who have started treatment on therapy until they die. In the next section, we
provide an algorithmic approach for finding lower bounds and upper bounds.
4.3 APPROXIMATE SOLUTIONS AND PERFORMANCE GUARANTEE
Computing PoN is intractable as it involves solving MDP formulations with countable state
spaces. Instead, we compute a lower bound on PoN by the difference between a lower bound
on the best performance in the abandonment-permitted setting and an upper bound for that
in the nonabandonment setting. That is,
PoN ≥ φ
(
max
pi∈Π
Jpi(S)
)
− φ
(
max
pi∈Π
Jpi(S)
)
, (4.4)
where φ(.), and φ(.) represent the lower bound and upper bound, respectively. To compute a
lower bound, we use the linear programming approach to ADP to derive efficient allocation
policies. To compute an upper bound we consider a relaxation of our formulation, as well as
a natural upper bound from ADP.
4.3.1 Lower Bound
We adapt the linear programming approach to approximate dynamic programming to com-
pute an efficient allocation policy, and use its performance as a lower bound. Note that the
same approach can be used to find a lower bound for the nonabandonment setting. Similar
to the case of finite state space and bounded rewards [Puterman, 1994, p.148], one can show
that J ≥ V for any J such that ‖J‖pc <∞, and
J(S) ≥ max
a∈A(S)
{
g(S, a) + λ Ea
{
J(S1)|S0 = S}} , S ∈ S.
Consider a distribution {c(S) : S ∈ S} such that c(S) > 0 for all S ∈ S. Proposition 2
provides an alternative characterization of the value function.
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Proposition 2 Given U ≥ v, then V is the unique solution to
min
∑
S∈S
c(S)
|S|+ 1 J(S) (4.5a)
s.t.
J(S) ≥ g(S, a) + λ Ea
{
J(S1)|S0 = S} , a ∈ A(S), S ∈ S, (4.5b)
|J(S)| ≤ (|S|+ 1)U, S ∈ S. (4.5c)
Proof: Define the dynamic programming operator T by
(TJ)(S) := max
a∈A(S)
{
g(S, a) + λEa
{
J(S1)|S0 = S}} , S ∈ S.
Suppose J ′ ≥ J component-wise, then (TJ ′) ≥ (TJ). In addition, Assumption 1 implies that
(see proof of Lemma 1) T is a contraction in the Banach space induced by ‖ · ‖pc [Puterman,
1994, Theorem 6.10.4, p.236]. Moreover, for any J such that ‖J‖pc <∞ one has that
lim
n→∞
‖T nJ − V ‖pc = 0.
Note that V is a feasible solution to (4.5), and that all feasible solutions attain finite
objectives. Consider a feasible J ; since J ≥ TJ one has that TJ ≥ T 2J ≥ T 3J ≥ . . ..
However, the sequence T kJ converges to V , thus we conclude that J ≥ V , which implies
that ∑
S∈S
c(S)
|S|+ 1J(S) ≥
∑
S∈S
c(S)
|S|+ 1V (S),
implying that V is the unique optimal solution to (4.5). ¤
Formulation (4.5) has countably many constraints and variables. We approximate its
solution in two steps. First, we approximate the value function V using an affine combination
of basis functions, so as to reduce the number of variables. Second, we limit the number of
constraints by sampling the states that are most likely to be visited by the optimal policy.
In addition, we use structural properties of the optimal policy under such approximation
to limit the number of actions worthy of consideration (note that A(S) grows exponentially
with the size of S).
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Value function approximation. We approximate V using an affine combination of basis
functions:
Vˆα(S) := α0 +
∑
i∈I
∑
p∈P
αi,p Yi,p +
∑
r∈R
αr Xr, S ∈ S. (4.6)
In this approximation, one may interpret αi,p as the marginal change in the expected QALYs
of the population if one patient is added to infected state i and treatment phase p. Similar
interpretation holds for αr. Our first approximation consists of restricting attention to
feasible solutions to (4.5) of the form Vˆα. One can show that imposing |Vˆα(S)| ≤ (|S|+1)U,
for all S ∈ S is equivalent to ‖α‖∞ ≤ U , where ‖.‖∞ denotes the uniform norm.
By considering the affine value function approximation, the optimal allocation policy is
of state-dependent priority-rule type.
Proposition 3 For any α and state S, the action maximizing the right-hand side of (4.5b),
when the value function is replaced by the approximation in (4.6), is that assigning treatment
according to the priority rule induced by the rating
σi,p(α, S) := (−1)p
(
αi,pdi,p − αi,p−1di,p−1 +
∑
i′∈I
αi′,pρ
p
i,i′ − αi′,p−1ρp−1i,i′ +∑
r′ αr′Xr′µr′ωr′,r
Nr
(νr,h,p − νr,h,p−1)− (ui,p − ui,p−1)
)
,
for all i ∈ I, p ∈ P .
Proof: Consider the set of constraints (4.5b) associated with S ∈ S. We have
Ea
{
X1r |S0 = S
}
= Dr(S)−Xrµr
∑
r′
∑
h
∑
p
ωr,r′νr′,h,p
Nr′
(ar′,h,p − ar′,h,p+1),
Ea
{
Y 1i,p|S0 = S
}
= Di,p(S)− di,p(ai,p − ai,p+1) +
∑
i′∈I
ρpi′,i(ai′,p − ai′,p+1), i ∈ I, p ∈ P.
Using Ea
{
Y 1i,p|S0 = S
}
and Ea {X1r |S0 = S}, one can rewrite (4.5b) as a single nonlinear
constraint∑
i∈I
∑
p∈P
((αi,p − ui,p)Yi,p − λαi,pDi,p(S)) +
∑
r∈R
((αr − 1)Xr − λαrDr(S)) + (1− λ)α0 ≥
λ max
a∈A(S)
{∑
i∈I
∑
p∈P
αi,p
(
ui,p(ai,p − ai,p+1) +
∑
i′∈I
ρpi′,i (ai′,p − ai′,p+1)− di,p (ai,p − ai,p+1)
)}
.
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For a fixed α, the right-hand side above can be rewritten as the maximization of a linear
function of α
max
{∑
i∈I
∑
p∈P
σi,p(α, S) zi,p :
∑
i∈I
(zi,1 + zi,2) ≤ K , 0 ≤ zi,p ≤ Yi,p−1 i ∈ I , p = 1, 2
}
.
(4.7)
The maximization problem in (4.7) is a bounded knapsack problem with equal weights;
therefore, it is greedily solvable. Thus, for each state S, σi,p(α, S) induces a strict priority-
rule policy. This proof is for the general case. One can use a similar argument for the
nonabandonment case. ¤
Each σ is an ordered list of (i, p) pairs, so for each S, the allocation is found by considering
(i, p) pairs in the order given by σ. Note that in our settings, transitions in treatment phases
are triggered exclusively by actions, thus, it suffices to consider ρpi,i′ = ρ
p,p′
i,i′ . Proposition
3 shows that rather than considering all actions in A(S), we only need to consider those
induced by priority lists.
Example 2 Suppose that R = {1, 2}, H = {1}, K = 10, and consider abandonment-
permitted policies. Table 2 shows a possible state and priority list (e.g., patients in state
(r = 1, h = 1, p = 1) have the highest priority). Following such a priority list, we see that
all patients in state (r = 1, h = 1, p = 1) receive treatment, as well as three patients in state
(r = 2, h = 1, p = 0). Note that four patients in state (r = 2, h = 1, p = 1) do not receive
treatment despite being currently on treatment, that is, they are moved to post-treatment
phase.
Table 2: Assigning treatment according to a priority list
Priority r h p Number of patients Allocated treatment
1 1 1 1 4 4
2 2 1 0 3 3
3 2 1 1 7 3
4 1 1 0 2 0
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Define Σ as the set of all possible permutations of elements in I × P . For σ ∈ Σ and
S ∈ S, define
Y σi,p(S) := Di,p(S)− di,p
(
aσi,p(S)− aσi,p+1(S)
)
+
∑
i′
ρpi′,i
(
aσi′,p(S)− aσi′,p+1(S)
)
,
Xσr (S) := Dr(S)−Xrµr
∑
r′
∑
h
∑
p
ωr,r′νr′,h,p
Nr′
(aσr′,h,p(S)− aσr′,h,p+1(S)),
where aσ(S) ∈ A(S) denotes the greedy ART allocation associated with permutation σ (as
illustrated in Example 2), and Di,p(S) and Dr(S) are finite state-dependent constants.
Constraint sampling. By considering the priority-rule policies and imposing constraints
(4.5b) for a finite sample of states, one can write the approximation problem as
RLP (c,S) : min
∑
S∈S
c(S)
|S|+ 1
(
α0 +
∑
i∈I
∑
p∈P
αi,p Yi,p +
∑
r∈R
αr Xr
)
(4.8a)
s.t.
D(S) + (1− λ)α0 +
∑
i∈I
∑
p∈P
αi,p
(
Yi,p − λY σi,p(S)
)
+∑
r∈R
αr (Xr − λXσr (S)) ≥ 0, σ ∈ Σ, S ∈ S¯, (4.8b)
‖α‖∞ ≤ U, (4.8c)
where D(S) depends only on S, and S¯ corresponds to m states in S sampled according to
the distribution c [de Farias and Van Roy, 2004]. We design an exact algorithm to find the
optimal solution of RLP (c,S), which we use to construct an efficient allocation policy.
Algorithmic approach. RLP (c,S) is a linear program with n := |I| |P | + 2 |R| + 1
variables, and |Σ|m + 2n constraints. Recall that Σ contains all permutations of I × P , in
particular, |Σ| = (|I| |P |)!. In our numerical study in Section 4.4, we have |Σ| = 300! ≈ 10614
( |Σ| = 25! ≈ 1025 policies in nonabandonment setting) so one cannot explicitly formulate
RLP (c,S).
Let Σ(S), a subset of Σ, be a set of priority-rule policies for state S. Solve RLP (c,S)
for a fixed c and S, imposing constraints (4.8b) only for σ ∈ Σ(S), and let α denote the
optimal solution to (4.8). If for each state S the priority σ(α, S) is included in Σ(S), then
one concludes that α is optimal when one includes all constraints in RLP (c,S) (i.e., those
associated with policies in Σ \ Σ(S)); on the other hand, if σ(α, S) is not included in Σ(S),
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then one should add σ(α, S) to the set of “plausible” policies. The observation above allows
us to solve RLP (c,S) iteratively: We use a few clinically based guidelines (such as WHO
recommendations) to construct an initial set of permutations Σ(S) for each S ∈ S. If
σ(α, S) /∈ Σ(S), where α solves RLP (c,S), then we add σ(α, S) to Σ(S) and re-solve. Since
|Σ| < ∞, the outcome of the procedure is the solution to RLP (c,S), although the number
of steps necessary to converge will depend on the initial set of policies considered (in our
numerical experiments in Section 4.4.1, we find that only a reasonably small number of
priority lists is added prior to convergence). Algorithm 1 formalizes this iterative procedure.
In addition to the above algorithm, we add a set of empirical lower bound constraints
Vˆα(S) ≥ V¯α(S) for a relatively small subset Sˆ ⊂ S to the RLP (c,S), where V¯α(S) is
the value function calculated by the ADP simulation under a policy induced by α. The
objective here is to recover the bounding property of the approximation, which might be
lost due to insufficient sampling of constraints. Our results in Section 4.4.1 indicate that
these constraints, which we believe are novel in the ADP literature, significantly improve the
quality of the approximation.
Algorithm 1 Solving RLP (c,S)
For each S ∈ S find an initial set of policies Σ(S).
Let α be a solution to RLP (c,S).
while σ(α, S) /∈ Σ(S) for all S do
Set Σ(S) := Σ(S) ∪ {σ(α, S)}.
Re-solve RLP (c,S).
Return α as an optimal solution to RLP (c,S).
We now discuss how to select c and S. de Farias and Van Roy [2004] show that c regulates
the quality of the approximation and can be used to target some regions in S where we need
good approximations. We are interested in regions in the state space that are more likely to
be visited by the optimal policy, which is not available. We select c and S so that: (i) its
computation is tractable; and (ii) it generates a policy via solving RLP (c,S) that is likely
to visit states that have larger weights according to c. Regarding (i), we use cˆpi,T as the
empirical counterpart of c, where pi is an allocation policy and T is the simulation period
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(see Section 4.7 for details). Regarding (ii), we use the following procedure: Starting from
a policy pi0, we use cˆpi0,T to sample m states, which we denote by S0, to formulate and
solve RLP (cˆpi0,T ,S0) via Algorithm 1. At each iteration k, an optimal solution αk is used
to compute cˆpik,T . We sample new states according to cˆpik,T and repeat the procedure until
|αk − αk−1| ≤ ². We address the convergence of Algorithm 2 in Section 4.4.1.
Algorithm 2 Finding efficient allocation policies
Initialize pi0 and set k = 0.
while |αk − αk−1| > ² do
Compute cˆpik,T and sample Sk according to cˆpik,T .
Add Vˆ (S) ≥ V¯αk(S), S ∈ Sˆ to RLP (cˆpik,T ,Sk).
Solve RLP (cˆpik,T ,Sk) and set αk+1 := α∗.
Set k := k + 1.
Return αk.
4.3.2 Upper Bound
As noted in Section 2.2, finding upper bounds is hard, and existing techniques do not apply
in our setting. In this section, we propose two techniques to compute upper bounds for our
problem.
Relaxation-based upper bound. Consider our formulation with every infected patient
replaced by two “clones”. The first clone (type 1) contributes to the transmission of the
disease and does not contribute to value function. We assume that the health progression
for type 1 clones is stochastically equivalent to that of a patient not on treatment. The
second clone (type 2) adds to the value function and does not contribute to transmitting the
disease. We assume that type 2 clones are always in the best health state. Upon infection,
susceptible individuals are replaced by two clones as well. Figure 6 illustrates this procedure.
We assign treatment to each type of clones separately. Note that type 1 clones who are
on treatment are less likely to infect susceptible individuals though their health progression
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Figure 6: Schematic view of the procedure for finding the upper bound
is not affected by treatment. We show that the optimal policy to assign treatment doses
to type 1 clones to maximize the value function is of priority-rule type. This will enable
us to assign treatment doses to clone 1 patients according to priority-rule type list. The
assignment procedure is similar to Example 2.
Lemma 2 If dr ≤ di,p for all r, i, p and we have random mixing, the optimal policy to treat
type 1 clones is giving treatment according to priority rule induced by the rating
σr,h := cr(νr,h,0 − νr,h,1) ∀r, h.
Proof: In random mixing, the optimal one-step policy can be obtained by solving the
following problem
max
{∑
r
∑
h
cr(νr,h,0 − νr,h,1)ar,h :
∑
r
∑
h
ar,h ≤ K, ar,h ≥ 0
}
,
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which is a knapsack problem with uniform weights that can be solved greedily. One can also
show by sample path arguments that a susceptible individual is more favorable for the value
function than an infected individual since dr ≤ di,p, and infected individuals transmit the
disease. Therefore, the optimal one-step policy is optimal. ¤
Since type 2 clones are always in the best health state, treatment is almost irrelevant.
However, patients on treatment are less likely to die. Therefore, it is optimal to assign all
treatment doses, no matter to whom. We assume that νr,h,p = νr,h′,p for all h and h
′. In this
setting, we have an upper bound for the value function.
Proposition 4 If all assumptions of the new formulation hold and we have random mixing,
the solution to the system described above provides an upper bound for the stochastic dynamic
programming problem.
Proof: We show that at each time in the system described in Proposition 4: (i) susceptible
individuals are less likely to become infected, and (ii) infected patients are less likely to die.
Therefore, by following a sample path argument, this system has more expected individuals
at each time than the original system. On one hand, treated patients live longer and they
have more opportunities to infect susceptible individuals. Therefore, to eliminate this effect
of treatment on transmission, we consider the health progression of type 1 clones to be
similar to that of a patient in absence of treatment. On the other hand, treatment reduces
infectivity and patients on treatment are less likely to transmit the disease. We capture this
effect by finding the optimal policy to treat type 1 clones by Lemma 2. Thus, at each time
susceptible individuals are less likely to become infected. Note that type 1 clones do not
contribute in value function. In addition, type 2 clones are always in the best health state
and they are more likely to live longer than patients in the original system. Therefore, at
each time we have more infected patients who contribute in calculating the value function.
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Proposition 4 provides an upper bound when mixing is random. We use this upper bound
as an approximated upper bound for the settings where mixing is not random.
Heuristic upper bound. We know that when all states appear in (4.8), the approximate
value function provides an upper bound for the actual value function, i.e., Vˆα(S) ≥ V (S).
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Since we sample finitely many states, this property does not necessarily hold. Our second
bound is based on the conjecture that as more states are included in the sample, the approx-
imation approaches an upper bound, and that the marginal change in the approximation is
decreasing in the size of the sample. Let Vˆα(m)(S) be the approximate value function, where
α(m) is the solution of Algorithm 2 by considering m sample states. We use the observa-
tion above to design an iterative procedure: We start from a finite sample state. At each
iteration we double the sample size and calculate Vˆα(2m)(S). If
∣∣∣Vˆα(2m)(S)− Vˆα(m)(S)∣∣∣ ≤ ²,
then we stop and consider Vˆα(m)(S) as the heuristic upper bound. Algorithm 3 formalizes
this approach.
Algorithm 3 Heuristic upper bound
Set m = 1000, and find Vˆα(m)(S) via Algorithm 2.
while
∣∣∣Vˆα(2m)(S)− Vˆα(m)(S)∣∣∣ > ² do
Establish new S by doubling the sample size.
Solve (4.8) via Algorithm 2 to find Vˆα(2m)(S).
Return Vˆα(m)(S).
4.4 NUMERICAL STUDY
In this section, we estimate PoN by using a lower bound on the performance in the abandonment-
permitted setting and an upper bound for that in the nonabandonment setting. In the pro-
cess, we show that the the policies produced by the ADP framework are close to optimal.
4.4.1 Computational Issues
Each decision epoch is considered to be three months Shechter et al. [2008]. Recall that the
health of patients is represented by the CD4 count. We discretize the CD4 count range into
five categories used in practice by policy makers. Therefore, we have five health categories
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for the pre-treatment and post-treatment phases, and 55 triplet4 health categories for on-
treatment phase: with this, one has that |Σ| := 300! ≈ 10614 (|Σ| := 25! ≈ 1025 in the
nonabandonment setting). We use the Braithwaite et al. [2011] simulation model, which
is validated with data from western Kenya, to simulate the progression of the disease for
100,000 patients in order to estimate the progression probabilities. The calibration of other
parameters in the model is similar to that in the large-scale HIV simulation model (see
Section 3.5). We initialize Σ(S) by using WHO recommendations, and we set T = 75 years,
λ = 0.96, and
∣∣S∣∣ = 1000.
Within Algorithm 2, we consider a smooth policy update, so that αk = αk−1 + (αk −
αk−1)k−3/4. This type of policy update has been used in similar works to guarantee conver-
gence5: see, for instance, Farias et al. [2011]. Considering the interpretation of α as the total
discounted life-years contributed by an individual (
∑∞
j=0 λ
t = 25), we choose U = 250. We
select S0 so that it represents the current state of the HIV epidemic in Sub-Saharan Africa.
In our numerical experiments, we focus on maximizing life expectancy, i.e., we set ui,p = 1
for all (i, p) ∈ I × P .
In our experiments, we observe that our algorithms converge rapidly across all coverage
levels: For example, in Algorithm 2, for each state S ∈ S the algorithm adds less than
10 policies to Σ(S) prior to convergence (this is despite the fact that |Σ| is huge). We
illustrate the effect of empirical lower bound constraints on the quality of the value function
approximation in Figure 7. On the x-axis we show V¯α?(S) which is the simulated value
function under α?, where α? is the optimal solution to the approximation problem. On the
y-axis we show Vˆα?(S) which is calculated by plugging α
∗ into (4.6) for 100 states chosen
randomly from S. As can be seen, adding the empirical lower bound constraints significantly
improves the quality of our approximations.
4Recall that for the health of on-treatment patients we consider a vector of three components, where each
component is a CD4 category and has 5 possibilities. One component is maximum CD4 count and should
be greater than or equal to other two components. Therefore, we have 55 possibilities.
5In our implementation, this smooth update is implemented after a few iterations and has little impact
on the quality of the approximation.
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Figure 7: Comparing approximated and simulated value function
4.4.2 Benchmark Policies
We use WHO recommendations as a benchmark, and consider its performance as our base-
line. Following WHO guidelines, drugs are assigned upon availability to the sickest patients
in the population, and the patient receives treatment until she dies. In addition, treatment
initiation is recommended only when a patient’s CD4 count goes below 350 cells/mm3 [WHO,
2012].
State-independent priority-rule policies are appealing in practice, and most policy makers
are interested in this type of policy [Bertsimas et al., 2013]. For the second benchmark, we
restrict our attention to state-independent priority-rule policies and provide two methods
for finding state-independent allocation policies.
In the first method, we design a state-independent priority list by exploiting the single-
patient model. For each infected state i we run the Braithwaite et al. [2011] simulation
model to find the expected lifetime of a patient with and without treatment. We consider a
priority list that prioritizes patients according to the benefit obtained by starting treatment.
In the second method, we consider an initial priority list, and simulate the system ac-
cording to the priority list and find the objective function. Then, we randomly select two
elements in the list and exchange them. We simulate the system according to the new list,
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and if the performance of the new list is better than the previous list, we accept the new
list. We continue this procedure to find an efficient allocation policy. In our numerical
experiments in Section 4.4.3, we run the procedure for 1000 iterations. In addition, for de-
signing state-independent benchmark policies, we find an initial priority list by running the
single-patient model and use it as an initial priority list for the second method. Note that we
design state-independent benchmarks in both nonabandonment and abandonment-permitted
settings.
4.4.3 Results
Our results show that ADP policies outperform WHO recommendations by as much as 5%
when policy makers follow the nonabandonment strategy. For guaranteeing the quality of
the ADP policies, we calculate the heuristic upper bound in this setting. Table 3 shows the
improvement in the objective function and the heuristic upper bound in each coverage level.
Table 3: Nonabandonment ADP policies performance compared to WHO recommendations
(%)
Coverage 15 28 47 58 67 84 95
State-independent benchmark 0.9 1.2 3.0 3.6 4.6 4.6 4.8
ADP 1.2 2.4 4.0 4.1 4.9 4.9 4.8
Heuristic upper bound 17.2 14.8 12.6 9.2 6.5 5.6 5.3
We also test the performance of ADP policies in the abandonment-permitted setting
where policy makers may remove patients from treatment. Table 4 shows the improvement
in the objective function, relaxation-based upper bound, and heuristic upper bound in each
coverage level. In this setting, the ADP policies outperform WHO recommendations by as
much as 62%. Table 5 shows PoN lower bound estimates for each coverage. As can be seen,
the price of nonabandonment policies is as much as 41% of total discounted QALYs of the
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Table 4: Abandonment-permitted ADP policies performance compared to WHO recommen-
dations (%)
Coverage 15 28 47 58 67 84 95
State-independent benchmark 2.1 3.2 4.2 3.7 2.9 0.3 -2.6
ADP 16.0 55.2 52.6 50.5 45.0 42.8 37.5
Relaxation-based upper bound 60.9 62.2 59.3 57.0 52.6 48.1 43.2
Heuristic upper bound 67.7 64.4 61.6 56.3 51.9 48.1 43.3
whole population. Note that in the 15% coverage level, the lower bound on the price of
nonabandonment is negative. This is due to the loose upper bound in the nonabandonment
setting in that coverage level.
Table 5: Price of nonabandonment policies (%)
Coverage 15 28 47 58 67 84 95
Price -1.2 40.4 40.0 41.3 38.5 37.2 32.2
After developing resistant mutations, HIV-infected patients marginally benefit from
treatment. Keeping patients on treatment until they die hinders the opportunity of as-
signing the treatment dose to other patients who might benefit more. Our results show that
the opportunity cost in this setting is huge. Removing a patient from treatment may be
unethical to the patient. However, keeping a patient on treatment until she dies may be
unethical to other patients who need treatment. By removing patients from treatment, we
can treat a greater proportion of the infected population, and this results in more QALYs
for the whole population. However, we do not necessarily recommend following this policy;
we only quantify its costs.
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4.5 CASE STUDY: HIV SIMULATION IN SUB-SAHARAN AFRICA
In this section, we use the large-scale HIV simulation model described in Section 3.5 to test
the performance of allocation policies. This simulation model allows us to relax some of the
ADP assumptions, such as the Markovian progression, and the fixed sequence of treatment
phases.
4.5.1 Results
Our analysis indicates that the ADP policies indeed outperform the benchmark policies
in terms of total and discounted total population. Table 6 shows the objective function
improvement by our policy for each coverage level compared with WHO recommendations.
As can be seen, the ADP policies outperform WHO recommendations by as much as 8%.
Table 6: Performance of policies compared to nonabandonment policy (%)
Coverage 15 28 47 58 67 84
Nonabandonment state-independent benchmark -1.9 -3.1 -2.4 -4.2 -0.7 -4.3
Nonabandonment ADP 4.1 0.6 0.1 0.4 2.1 0.8
Abandonment-permitted state-independent benchmark 1.5 2.2 4.8 4.8 6.7 4.7
Abandonment-permitted ADP 4.8 2.9 7.2 7.1 8.2 6.2
4.5.2 Policy Insights
To gain insight into the ADP policies, we consider how ADP policies assign and remove
patients from treatment. Since the ADP policy is state-dependent, we focus on two factors
which are important for policy makers: prevalence, and coverage. We analyze the ADP pol-
icy in a variety of prevalence and coverage levels. Table 7 shows how the ADP policies assign
treatment, where rows correspond to coverage levels and columns correspond to prevalence
levels. We consider three categories for coverage and prevalence: low, medium, and high. As
can be seen, both risk and health are important for assigning treatment. In most scenarios,
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Table 7: Risk and health priorities in ADP assignment
hhhhhhhhhhhhCoverage
Prevalence
Low [0,3%) Medium [3%,7%) High [7%,15%)
Low [0, 35%)
Poly>Mono>Child Poly>Child>Mono Poly>Mono>Child
Moderate>Sick>Healthy Sick>Healthy>Moderate Moderate>Sick>Healthy
Medium [35, 70%)
Child>Poly>Mono Poly>Mono>Child Poly>Mono>Child
Healthy>Moderate>Sick Moderate>Healthy>Sick Healthy>Moderate>Sick
High [70%, 100%)
Poly>Mono>Child Poly>Mono>Child Poly>Child>Mono
Moderate>Healthy>Sick Healthy>Sickest>Moderate Moderate>Sick>Healthy
Note that Poly stands for polygamous and Mono stands for monogamous
polygamous patients have the highest priority for receiving treatment. The ADP policies
then prioritize monogamous patients and finally children. In most scenarios, the ADP poli-
cies first prioritize patients having a moderate health state. Moreover, our analysis shows
that risk is relatively more important than health. This result differs markedly from WHO
recommendations, which prioritize the sickest patients and does not consider risk.
Table 8 provides details on the assignment procedure. The risk categories are shown in
rows, and the health categories are shown in columns. Each entry in the table shows the
ranking associated with the “risk-health” pair in the priority list of the ADP policy associ-
ated with the scenario for high prevalence and low coverage. We sum the priorities in each
column to find an aggregate priority for each health category. Similarly, we calculate the
aggregate priority for each risk category. Table 8 shows that health and risk are important
in assigning treatment. In this scenario, polygamous patients have the highest priority in
receiving treatment, then the monogamous patients and finally infected children. The ADP
policy prioritizes patients with moderate health state, then the sickest and finally the health-
iest patients. We also investigate when the ADP policies remove patients from treatment in
a variety of prevalence and coverage levels. In contrast to nonabandonment policies, ADP
policies mainly remove patients from treatment when their maximum CD4 reaches the high-
est health category. Loosely speaking, ADP policies stop treatment when CD4 count reaches
350 cells/mm3 or starts declining. This result is observed in almost all coverage and preva-
lence levels. We also compare the mean treatment time for patients under each policy. Our
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Table 8: Aggregated priorities for health and risk under the ADP policy
Health (CD4 categories)
[0,50) [50,100) [100,200) [200,350) [350,∞)
Risk Aggregated risk
0 20 24 21 23 18 106
1 22 8 16 15 25 86
3 11 14 5 19 17 66
5 4 3 10 9 12 38
7 6 13 1 2 7 29
Aggregated health 63 62 53 68 79
results show that the mean treatment time for the ADP policies are almost 30% of the mean
treatment time for WHO policies. Figure 8 shows the mean treatment time under WHO
and ADP policies for different coverage levels. Moreover, we define “effective coverage” as
the total proportion of the infected population who receive treatment at some point in their
life; that is, the long-term proportion of the infected population who receive treatment. The
ADP policies have the highest effective coverage, so that they treat a greater proportion of
the infected population. Even in low coverage levels the ADP policies treat more than 85%
of the infected population at some point. Since the number of available treatment doses has
increased in Sub-Saharan Africa during the past decade, we consider a setting in which the
number of treatment doses increases according to the trend of ART growth in Sub-Saharan
Africa. We consider the initial coverage of 58% and test the performance of the ADP policies
against the WHO recommendations via the HIV simulation model. Our analysis shows that
the ADP policies outperform the WHO recommendations by 1%.
4.6 HIV TRANSMISSION DYNAMICS FORMULATION
In this section, we describe our transmission model which extends the transmission model
used in Garnett and Anderson [1994]. They use a deterministic compartmental framework
to describe the transmission dynamics. They model the dynamics of the system by using a
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Figure 8: Comparison of treatment time under WHO and ADP policies
deterministic system of differential equations. In their model, the total number of susceptible
individuals in risk group r who become infected in a period is calculated by
νXr
∑
r′
ωr,r′
Yr′
Nr′
,
where Yr′ is the total number of infected individuals in risk group r
′, and ν denotes the
transmission probability per partnership.
Fix a state S ∈ S, and let pr(S, a) denote the probability of contagion of a susceptible
individual in risk group r. Let Ar,n denote the event that a susceptible individual in risk group
r becomes infected in his/her n-th partnership, and let Br denote the number of partnerships
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established in a period which we assume has the distribution qr(n), n = 0, 1, 2, · · ·Lr.
Therefore, we have
pr(S, a) = 1−
Lr∑
n=0
P (
n⋂
m=1
Acr,m)qr(n) = 1−
Lr∑
n=0
(1− ψr(S, a))nqr(n),
where we assume that the events Ar,m are independent and equally likely, and ψr(S, a) de-
notes the probability that a random partnership results in infection of a susceptible individual
with risk r. Following Garnett and Anderson [1994] one has that (in the setting where policy
makers may remove patients from treatment)
ψr(S, a) =
∑
r′∈R
ωrr′
∑
h,p νr′,h,p (Yr′,h,p + ar′,h,p − ar′,h,p+1)
Nr′
,
where ωrr′ is the probability that a susceptible individual of risk r forms a partnership with
someone of risk r′, and the term
∑
h,p(Yr′,h,p+ar′,h,p−ar′,h,p+1)/Nr′ represents the probability
that a partnership is established with an infected patient after taking the action, conditional
on such a partner having risk r′. Note that νr′,h,p, the probability of transmission in a
partnership, depends on the risk group r′, health state h, and treatment phase p of the
infected partner.
By using the Taylor series expansion of (1 − ψr)n we have (suppressing S and a for
simplicity)
(1− ψr)n ≈ 1− nψr +O(ψ2r
n(n− 1)
2
), (4.9)
where O denotes the error order for this approximation. By using (4.9) we approximate
pr(S, a) by pˆr(S, a). Therefore, we have
pˆr(S, a) = 1−
Lr∑
n=0
(1− nψr)qr(n) = µrψr(S, a), (4.10)
where
‖pr(S, a)− pˆr(S, a)‖ ≤ ψ
2
r
2
[
V ar(n) + µ2r − µr
]
.
In our setting, ψr < 0.01 and µr < 10, and the maximum error is relatively small.
The partnership patterns among activity groups can be described by mixing matrices.
Define Ω = [ωrr′ ] as a mixing matrix where ωrr′ is the probability that a person in risk group
r forms a partnership with another person in risk group r′. The structure of this matrix
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determines the mixing patterns. Two extreme cases are assortative and disassortative mixing.
In assortative case, individuals in the same risk group form partnerships together and in the
disassortative case, individuals tend to form partnerships with other risk groups. Between
these two extreme cases, there is also random mixing in which the probabilities in the matrix
is proportional to the total supply of sexual partnerships of risk group r. In other words,
in random mixing we have ωrr′ =
Nr′cr′∑
r′′ Nr′′cr′′
, where Nr is the total number of individuals
in risk group r, and cr is the mean number of partnerships an individual forms in a period.
In our study we use a mixing pattern which is common in mathematical studies of STDs.
Let ∆ = [δrr′ ] be the identity matrix and θ be the degree of assortative mixing. We use the
following mixing pattern
ωrr′ = (1− θ)δrr′ + θ
( Nr′cr′∑
r′′ Nr′′cr′′
)
.
This approach is suitable for numeric simulations and can capture many different mixing
scenarios [Garnett and Anderson, 1994]. We set θ = 0.7 as our base case.
4.7 SAMPLING CONSTRAINTS
Regarding the selection of c, one can show that minimizing (4.8) is equivalent to minimizing∑
S∈S
c(S)
|S|+ 1
∣∣∣Vˆα(S)− V (S)∣∣∣ .
As noted by de Farias and Van Roy [2004], c regulates the quality of the approximation across
S, and can therefore be used to target certain regions of the state space where one aims to
obtain better approximations. In that regard, we would like to obtain better approximations
in the states that are most likely to be visited in the near future when the optimal policy is
used. For a policy pi, define the distribution cpi by
cpi(S) := (1− λ)
∞∑
t=0
λtPpi
{
St = S|S0} , S ∈ S,
where S0 is an initial state representative of the current population, and λ is the discount
factor. We would like to use cpi∗ in the objective function of (4.8), and also in sampling
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S through ψ, as prescribed in de Farias and Van Roy [2004, Theorem 3.1., p.469]. Unfor-
tunately, one does not have prior access to pi∗. Let pi0 denote an initial allocation policy.
Finding cpi0 is computationally intractable, thus, we settle for approximating it using its
empirical counterpart, cˆpi0,T , which is given by
cˆpi,T (S) := (1− λ)
T∑
t=0
λt1{St(ω)=S}, S ∈ S,
where {St(ω) : t ≥ 0} represents the outcome of a simulation, and T > m denotes the sim-
ulation budget.6 We use this simulation run to select S as well: computing ψ is infeasible,
thus we approximate it as cˆpi,T . Note that the underlying motivation is that on most sim-
ulation runs, states are visited at most once, thus we approximate Ppi {St = S|S0 = S ′} ≈∑N
n=1 1{St(ωn)=S}/N , where N is the number of replications. This results in ψ ≈ c.
4.8 CONCLUSIONS
This chapter quantifies the price of following nonabandonment policies in HIV treatment
in resource-limited settings. First, we develop a Markov decision process model to opti-
mize the allocation of scarce HIV treatment for a broad class of admissible policies. Then,
we consider two classes of admissible policies: (i) nonabandonment, and (ii) abandonment-
permitted. The price of nonabandonment is the difference between the optimal solutions of
the above settings. Since the MDP formulation has unbounded state space for each prob-
lem, we estimate a lower bound for the price of nonabandonment by the difference between
a lower bound on the performance in the abandonment-permitted setting and an upper
bound of that in the nonabandonment setting. We use the linear programming approach
to approximate dynamic programming to develop an algorithmic approach to find an effi-
cient allocation policy. By providing upper bounds for our approximations we show that the
policies produced by our method are close to optimal. Our results show that the price of
following the nonabandonment policies is as much as 41% of the total discounted QALYs of
6In our numerical study we take the average over many replications.
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the whole population. We compare the performance of proposed policies with WHO recom-
mendations via the simulation model. Our results show that the ADP policies outperform
WHO recommendations by as much as 8%. Regarding the structure of the ADP policy,
we analyze how it prioritizes patients for initiating treatment and when it removes patients
from treatment in a variety of scenarios. In assigning treatment, both risk and health status
are important, but risk is relatively more important than health. In particular, the ADP
policies in most scenarios prioritize polygamous patients, then monogamous and finally chil-
dren. The ADP policies mostly prioritize patients with moderate health state. In removing
patients from treatment, the ADP polices remove patients whose maximum CD4 count on
treatment reaches the best health state. By removing patients from treatment policy makers
can treat a greater proportion of the population which results in more QALYs for the whole
population.
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5.0 THE EFFECT OF PIPELINE DRUGS ON HIV TREATMENT
5.1 INTRODUCTION
The decision of when to start HIV therapy is an important clinical decision that remains
controversial. Because timing decisions are not amenable to randomized controlled trials, this
problem has been widely modeled and discussed in published reports [Braithwaite et al., 2008,
Harrington and Carpenter, 2000, Ho, 1995, Holmberg et al., 2004, Lane and Neaton, 2003,
Shechter et al., 2008]. These models generally seek to identify clinical conditions under which
a patient should initiate ART so as to maximize his/her quality-adjusted life expectancy.
They consider many factors, such as the initial viral load and CD4 count, age, gender,
CD4 threshold and viral load threshold for initiating drugs, adherence, resistance, and HIV
mutations at baseline. However, these models have not considered the rate of development
of new antiretroviral drugs, assuming a fixed number of antiretroviral drugs assigned to a
fixed number of distinct mechanistic categories. However, these numbers are unlikely to
remain fixed over the time horizon of the model. We develop a model to address how
treatment recommendations regarding when to start, switch, and sequence ARV regimens,
would change with varying assumptions regarding the rates of new drug development, the
proportion of new drugs in existing classes versus new mechanistic classes, the patterns of
cross-resistance between new and existing mechanistic classes, and the toxicity of new drugs
compared to existing drugs either in the same class or in a new class.
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5.2 METHODS
We use the HIV simulation model of Braithwaite et al. [2008] to evaluate the outcomes
of patients treated under different assumptions about the availability and characteristics
of new antiretroviral drugs. The Braithwaite model is an individual microsimulation that
replicates the individual progression of disease (CD4 counts, viral loads, presence of muta-
tions, treatment status, etc.) and estimates HIV-related mortality as a function of those
individual patient characteristics [Braithwaite et al., 2005]. It incorporates baseline mor-
tality, HIV-related mortality and the toxicity of ARVs. A notable aspect of the model is
the mechanistic manner by which it represents the development of HIV antiviral resistance
[Braithwaite et al., 2005, 2006]. It can predict the time to treatment failure, survival, and
the development of HIV antiviral resistance [Braithwaite et al., 2005, 2006]. We modify it by
incorporating the arrival of new drugs, those within existing classes of drugs and the devel-
opment of new classes of antiretroviral agents. This allows the simulation to treat patients
with more cycles of therapy, and provides increased flexibility for changing to a different
drug combination after the development of resistance.
In our base case, we simulate a cohort of patients treated under the assumption of the
availability of three classes of antiretroviral drugs, without the future development of new
drugs, which is a common assumption used by most HIV treatment models. We compare
the life expectancy and quality-adjusted life expectancy of an identical cohort treated under
multiple scenarios assuming the future development of new drugs within existing classes and
for new classes. We estimate the optimal criteria for the initiation of ARV in the presence of
pipeline drugs. Because of considerable uncertainty regarding variability in the effectiveness
and toxicity of new drugs, we explore a wide variety of assumptions. Based on historical
data, we empirically estimate 1) the probabilistic arrival of HIV pipeline drugs for both
current and brand new classes of drugs, and 2) the likelihood of cross-resistance between
new and existing mechanistic classes.
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5.2.1 Analyzing Inter-Arrival Time of Pipeline Drugs
We fit the probability distribution for the inter-arrival times of new drugs, defined as when
the drug was approved by the Food and Drug Administration (FDA), to an exponential
distribution with rate λ using data from the FDA database [Food and Drug Administration,
2010]. The parameters of distributions are estimated by the maximum likelihood estimator
(MLE) technique. Goodness-of-fit is tested by Quantile-Quantile plot and Kolmogorov-
Smirnov tests [Montgomery et al., 2003]. The statistical programming language “R” was
used for all estimates and statistical tests. We model the arrival of pipeline drugs as a Poisson
process. If the overall arrival process is a Poisson process with rate Λ, ie, PP (Λ), then, if the
arrival is of type i with probability pi, independent of everything else, then the i
th process
is PP (Λpi). This is referred to as splitting a Poisson process [Nelson, 1995]. We assume
that drug types split to new classes and existing classes according to a Bernoulli splitting
mechanism. Therefore, the arrival of new classes and new drugs belonging to existing classes
is also a Poisson process. Moreover, if a new drug belonging to an existing class arrives,
we assume that it will be uniformly distributed among current classes. A schematic view is
shown in Figure 9.
5.2.2 Cross-Resistance
The development of HIV antiviral resistance is complex, and mutations in the HIV genome
that confer resistance to a particular drug may also confer partial resistance to other drugs, a
phenomenon known as cross-resistance. Since cross-resistance will likely plague new drugs as
it does existing ones, we include the possibility of developing cross-resistance in new drugs
as well. Cross-resistance is substantially more likely in drugs within the same class than
between drugs of a different class [Johnson et al., 2010]. More specifically, mutations in the
nucleoside reverse-transcriptase inhibitors (NRTI) and non-nucleoside reverse-transcriptase
inhibitors (NNRTI) class are both in the Reverse Transcriptase gene, but there is no mutual
mutation among drugs in these classes, so these is no cross-resistance pattern among drugs
in the NRTI and NNRTI classes. Since mutations in the protease inhibitors (PI) class occur
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Figure 9: The arrival process of HIV pipeline drugs
in the Protease gene and in the NRTI and NNRTI class occur in Reverse Transcriptase gene
[Johnson et al., 2010], there is no cross-resistance among drugs in these classes. Therefore,
we assume that there is no development of cross-resistance between classes of drugs.
We model the probability distribution of cross-resistance pattern in each drug class.
The cross-resistance of new drugs is assumed to be equal to the cross-resistance probability
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distributions of existing drugs, i.e., if a new drug belongs to the NRTI class, it will follow the
resistance pattern of the NRTI class. The probability that a specific mutation will confer
resistance to a new drug is estimated by the proportion of drugs in that class for which the
mutation is known for conferring resistance. First, we find the total number of drugs for
which a particular mutation confers resistance. For example, in the NRTI class, the M41
mutation confers resistance only to Stavudine and Zidovudine, so the total number of drugs
for which M41 confers resistance is 2 [Johnson et al., 2010]. This procedure is repeated for all
mutations in each class. Then, the best probability distribution is fit to the number of drugs
for which each mutation confers a resistance. To determine the cross-resistance probability
in each class, we generate a random variate from the distribution and then divide it by the
total number of drugs in that class. We assume that mutations are independent and equally
likely to happen. We separate the mutations into two groups of major and minor mutations
and for each group we find the best probability distribution of number of drugs resistant to
that kind.
5.2.3 Efficacy and Toxicity of New Antiretroviral Agents
The efficacy of a particular drug is represented by its ability to decrease viral load. For the
base case, we assume that the viral load decrement of new drugs is equal to the average of
viral load decrements of drugs in the same class. The Braithwaite model assumes that the
toxicity of all classes of drugs is the same [Braithwaite et al., 2008], we also assume that
toxicity of new drugs will also be the same and equal to the previous toxicity level. In the
sensitivity analysis, we test scenarios in which the efficacy and toxicity of pipeline drugs are
different from existing drugs.
5.2.4 Scenarios Regarding When to Initiate ART
Successive populations of individuals with newly diagnosed chronic HIV infection were con-
sidered, each of them starting with CD4 count of 500 cells/mm3. We consider CD4 thresholds
starting from 50 cells/mm3 until 500 cells/mm3 with increments of 50 cells/mm3, which are
consistent with current guidelines [Braithwaite et al., 2008]. In addition, different starting
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age categories (30, 40, and 50) and baseline viral loads of 104, 104.5, 105 and 105.5 copies/mL
are modeled. Mean life-years and mean quality-adjusted life-years are calculated for pol-
icy making comparisons. In each category, the optimal CD4 count threshold for treatment
initiation is found. For each of these thresholds, the life expectancy is calculated and the
threshold with the maximum life expectancy is chosen as the optimal time for initiating the
therapy for each category.
5.2.5 Scenarios Regarding Sensitivity Analysis
We vary several model parameters to assess the impact on model predictions of the effect
of pipeline drugs on population survival. Specifically, we vary the inter-arrival time of new
drugs (all varied across 95% confidence limits of our estimates), the rate at which new drugs
accumulate mutations, the level of adherence across drugs, the effectiveness of new pipeline
drugs compared to existing drugs, and the toxicity level of new drugs. In scenarios where the
efficacy of the new drug is equivalent to the average of the existing drugs, the new drug is
added as an extra regimen when the patient has exhausted all existing regimens. However,
in sensitivity analysis where the new drug is better than existing drugs, we assume the new
drug is used after the first regimen has failed.
5.3 RESULTS
5.3.1 Probability Distributions
Table 9 shows the estimated parameter values for the exponential distributions, i.e., λ, and
the respective p-values indicating whether we reject the null hypothesis that the observed
distribution is an exponential distribution with rate parameter λ. The distribution of inter-
arrival times of drugs is exponential with mean 1
λ
= 7.69 months, which implies that the
arrival of new drugs follows a Poisson process with rate λ = 0.13. The Quantile-Quantile
plot for this fit is shown in Figure 10. The arrival process of a new drug is assumed to follow
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Figure 10: Quantile-Quantile plot for the goodness of fit for the arrival process
a split Poisson process [Nelson, 1995]. If a drug arrives, it will be from a new class with
probability p, and from current classes with probability (1 − p). Using the point estimate
method we have p = 6
31
. Using this estimate, the probability distributions and the p-values
for Kolmogorov-Smirnov goodness of fit test associated with these distributions are calculated
and shown in Table 9.
If the population distribution is exponential, it can be shown that the 100(1 − α)%
confidence interval for λ from a sample of X1, X2, · · · , Xn is
(χ22n;α
2
)/(2nX) < λ < (χ22n;1−α
2
)/(2nX),
where X is the mean of the sample and χ22n is a Chi-square distribution with 2n degrees of
freedom and Pr(χ22n > χ
2
2n;α
2
) = α
2
[Montgomery et al., 2003]. A 95% confidence interval for
inter-arrival times of each distribution is reported in Table 9.
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Table 9: Validity of exponential inter-arrival time distributions
Probability distribution p-value 95% CI
Inter-arrival time of new drugs Exp (λ = 0.13) 0.085 [0.09,0.181]
Inter-arrival time of new classes Exp (λ = 0.02) 0.725 [0.006,0.041]
Inter-arrival time of new drugs
belonging to existing classes Exp (λ = 0.104) 0.112 [0.068,0.147]
Table 10: Approval date of ARV classes
Drug Class Date of approval of the first drug
NRTI March 1987
PI Dec 1995
NNRTI June 1996
Fusion Inhibitor March 2003
Integrase Inhibitor October 2007
Entry Inhibitor August 2007
Table 11: The cross-resistance probability distributions
Drug Class Number of drugs Probability distribution of number p-value
of drugs resistant to a mutation
NRTI 7 Uniform[1, 4] 0.059
NNRTI 3 Uniform[1, 3] 0.042
PI 8 Poisson(λ = 3) 0.024
First, we test the assumption that if a new drug belonging to an existing class arrives, it
will be uniformly distributed among them. The approval date of the first drug in each class
is shown in Table 10 [Food and Drug Administration, 2010]. Between Dec 1995 and June
1996, when there were only two classes of drugs, two drugs were approved from the PI class.
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Table 12: The probability distribution of the number of drugs resistant to a mutation
Class Probability distribution Number of mutations
Major p-value Minor p-value Major Minor
NRTI Uniform[1, 4] 0.059 N/A N/A 8 N/A
NNRTI Poisson(λ = 2.44) 0.037 1 N/A 9 5
PI Poisson(λ = 3.25) 0.722 Poisson(λ = 2.88) 0.025 12 26
Assuming the uniform distribution, this event happens with probability 0.25. Between June
1996 and March 2003, when there were three classes of drugs, 11 drugs were approved from
which four belong to the PI class, five belong to the NRTI class and two belong to the NNRTI
class. We fit the uniform distribution to this data and the corresponding p-value is 0.08253.
Therefore, when we had two or three classes of drugs, the new drug was equally likely from
current classes in hand, supporting the assumption that new drugs are distributed equally
among existing classes.
The cross-resistance probability distributions are shown in Table 11 [Johnson et al.,
2010]. The best fitting distributions for the probability of cross-resistance within NRTIs and
NNRTIs are uniform; the probability of cross-resistance in the PIs is Poisson. For the other
three classes of new drugs (Fusion Inhibitors, Entry Inhibitors and Integrase Inhibitors) no
distribution can be fit since there is only one drug in each class by 2011.
Drugs in the NRTI class are divided into two groups, thymidine-associated mutations
(TAMs) and non-thymidine-associated mutations (Non-TAMs). Stavudine and Zidovudine
are TAMs and the other five are Non-TAMs. Two of ten existing mutations confer resistance
to both TAMs and Non-TAMs [Johnson et al., 2010], so the cross-resistance probability is
estimated to be 0.2 between TAMs and Non-TAMs. We differentiate between TAMs and
Non-TAMs for making the new regimens. The probability distribution of the number of
drugs resistant to a major or minor mutation is shown in Table 12.
Table 13 shows life-years and QALYs of patients in the base model for different age,
VL, and starting CD4 count categories. Table 14 presents the relative gain of life-years and
QALYs of identical cohorts simulated under conditions of no new pipeline drugs compared
to simulation with the stochastic arrival of new antiretroviral agents. The relative life-year
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gain less than 0.01 % is considered to be zero. Across all ages, viral loads and CD4 counts
at initiation of therapy, the life-year gain is at most 2% and in some scenarios this gain is
near zero. Table 15 shows the optimal CD4 count threshold for initiating the therapy for
each scenario for both the validated simulation model and the simulation model with the
inclusion of pipeline drugs.
Table 13: Life-years and QALYs
CD4 threshold=200 CD4 threshold=350 CD4 threshold=500
Age 30 years Life years QALYs Life years QALYs Life years QALYs
Viral Load
104.0 37.561 33.079 38.637 33.913 38.958 33.969
104.5 37.016 32.356 38.579 33.651 38.917 33.766
105.0 36.695 31.824 38.18 33.109 38.752 33.441
105.5 35.465 30.48 36.978 31.764 37.51 32.096
Age 40 years
Viral Load
104.0 29.247 25.924 30.043 26.544 30.195 26.473
104.5 28.638 25.214 29.775 26.162 30.318 26.467
105.0 28.685 25.067 29.807 26.043 30.207 26.248
105.5 28.269 24.499 29.261 25.345 29.624 25.538
Age 50 years
Viral Load
104.0 21.445 19.147 21.902 19.47 21.933 19.319
104.5 20.794 18.451 21.667 19.167 21.753 19.102
105.0 20.752 18.299 21.797 19.187 21.881 19.133
105.5 20.71 18.125 21.574 18.856 21.809 18.951
5.3.2 Sensitivity Analysis
The result of the analysis is reported in Tables 16, 17, and 18. Numbers in the table show the
gain in QALYs (in percent) by using the pipeline drugs. In the sensitivity analysis, we initiate
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Table 14: Relative life-years and QALYs gain due to pipeline (%)
CD4 threshold=200 CD4 threshold=350 CD4 threshold=500
Age 30 years Life years QALYs Life years QALYs Life years QALYs
Viral Load
104.0 0.00 1.14 0.37 1.75 0.00 1.62
104.5 0.58 2.24 0.14 2.01 0.00 1.92
105.0 1.06 3.32 1.23 3.58 0.11 2.62
105.5 4.53 7.65 3.99 7.26 3.29 6.63
Age 40 years
Viral Load
104.0 0.00 0.24 0.00 0.86 0.19 1.28
104.5 0.00 0.94 0.43 1.70 0.19 1.28
105.0 0.24 1.88 0.44 1.86 0.19 1.58
105.5 2.27 4.59 2.40 4.86 1.82 4.40
Age 50 years
Viral Load
104.0 0.00 0.00 0.00 0.05 0.00 0.21
104.5 0.00 0.11 0.78 1.55 0.86 1.79
105.0 0.48 1.47 0.78 1.55 0.86 1.79
105.5 1.79 3.33 0.78 2.08 0.86 2.01
treatment at CD4 count of 350 cells/mm3. The sensitivity analysis indicates that varying the
estimates of the inter-arrival times of new drugs, the rate of accumulation of resistance, the
patient’s adherence to treatment regimens, and the relative efficacy of pipeline drugs have
little effect on overall outcomes, but that the toxicity of pipeline drugs has a potentially large
effect on life expectancy. If the toxicity of pipeline drugs is reduced compared to existing
drugs (the pipeline drugs have a mortality relative risk of 1), the presence of new pipeline
drugs can increase the quality adjusted survival by as much as 13% in young patients with
high viral load.
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Table 15: The optimal CD4 count for initiating the therapy with and without pipeline
Age categories
30 years 40 years 50 years
VL Base Pipeline Base Pipeline Base Pipeline
4.0 450 450 450 450 300 450
4.5 450 450 450 450 450 450
5.0 450 450 450 450 450 450
5.5 450 450 450 450 450 450
Table 16: Sensitivity analysis for 30 year old patients
VL
4.5 5.0 5.5
Low Base High
Inter-arrival time 0.09 0.13 0.181 (1.75,2.01,2.02) (3.13,3.58,3.86) (6.84,7.26,7.47)
Rate mutations 0.16 0.18 0.2 (2.01,2.01,1.94) (3.59,3.58,2.95) (7.29,7.26,7.24)
Adherence 0.62 0.75 0.76 (1.08,2.01,2.01) (2.51,3.58,3.58) (6.08,7.26,7.26)
viral load decrement -1 0 1 (1.88,2.01,2.02) (3.58,3.58,3.58) (7.25,7.26,7.36)
Toxicity 1 1.5 1.7 (4.19,2.01,1.01) (7.41,3.58,2.34) (13.03,7.26,5.66)
Table 17: Sensitivity analysis for 40 year old patients
VL
4.5 5.0 5.5
Low Base High
Inter-arrival time 0.09 0.13 0.181 (1.13,1.70,1.70) (1.86,1.86,2.58) (4.13,4.86,4.87)
Rate of mutations 0.16 0.18 0.2 (1.70,1.70,1.70) (1.86,1.86,1.86) (4.32,4.86,4.73)
Adherence 0.62 0.75 0.76 (1.00,1.70,1.70) (1.16,1.86,1.95) (3.52,4.86,4.86)
Viral load decrement -1 0 1 (1.60,1.70,1.70) (1.86,1.86,1.94) (4.58,4.86,4.86)
Toxicity 1 1.5 1.7 (3.78,1.70,0.73) (5.15,1.86,1.09) (9.47,4.86,3.04)
5.4 DISCUSSION
Models with and without the inclusion of pipeline drugs support a similar policy for initiating
the therapy considering either life expectancy or quality-adjusted life expectancy. Consis-
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Table 18: Sensitivity analysis for 50 year old patients
VL
4.5 5.0 5.5
Low Base High
Inter-arrival time 0.09 0.13 0.181 (0.83,1.55,0.71) (0.69,1.55,1.55) (1.86,2.08,2.18)
Rate of mutations 0.16 0.18 0.2 (1.55,1.55,0.97) (1.55,1.55,0.78) (2.57,2.08,1.75)
Adherence 0.62 0.75 0.76 (0.44,1.55,1.55) (0.30,1.55,1.55) (1.40,2.08,2.08)
Viral load decrement -1 0 1 (1.55,1.55,1.55) (1.43,1.55,1.55) (2.08,2.08,2.56)
Toxicity 1 1.5 1.7 (1.98,1.55,1.04) (1.94,1.55,0.45) (5.78,2.08,1.78)
tent with current treatment recommendations, the base case model (that does not include
the availability of pipeline drugs) supports early treatment in most scenarios. In virtually
all scenarios, the model that includes the availability of pipeline drugs supports initiating
therapy at CD4 level of 500 cells/mm3. The quality-adjusted life expectancy gain from the
inclusion of pipeline drugs in all categories ranges from no gain to almost 8%. This translates
to almost 2.3 years of additional quality-adjusted life expectancy for a hypothetical healthy
30 year old HIV-infected patient with a VL of 105.5, and therapy initiated at the CD4 count
of 350 cells/mm3.
We find that the optimal time to initiate the therapy for HIV is sensitive to the existence
of pipeline drugs. This result is intuitive, as one expects the availability of more drugs would
prompt earlier initiation of therapy and switching between drugs more frequently. However,
the overall impact of new drugs is not large, primarily because there are already enough
regimens available. The base simulation model is calibrated for resource-rich environments
and in its current version, 17 drugs exist which might be interpreted as enough drugs for HIV
treatment in resource-rich environments. In the model, a patient remains on the last regimen
even if she has accrued resistance to that regimen and accrues some benefits from the last
regimen, although less than prior to becoming resistant to it. Imposing this assumption is
also biased against the effect of pipeline drugs.
This study has several limitations. Our data are from a cohort that is overwhelmingly
male, and thus our results may not apply to women. For policy recommendations, cost has
not been considered, which may have impact on policy recommendations. Our model does
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not include spreading of resistance patterns in the native viral population. As resistance
spreads, some newly infected individuals are infected with already resistant strains.
Toxicity of new pipeline drugs is the most important factor for improving the outcomes
of ARV. This finding is based on the assumption that there is currently a small but real
toxicity to existing HIV medications, which is supported in the literature but for which the
exact magnitude is not precisely known. The improvement of QALYs can be as high as 13%
in scenarios where pipeline drugs are not toxic. Therefore, the effort to make the new HIV
drugs less toxic should be considered as the highest priority.
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6.0 CONCLUSIONS
This dissertation applies mathematical models to address fundamental questions in HIV
treatment. Containing HIV is a primary global health issue and managing scarce HIV
treatment is a top priority. Antiretroviral drugs are the only treatment option for chronic
HIV infection and demand for them far exceeds the supply in resource-limited settings. The
area hit hardest by the HIV epidemic is Sub-Saharan Africa, where the majority of countries
have coverage levels of less than 50%. In Chapter 3, we developed a simulation model to
measure the effect of HIV treatment on the infected population size and the quantity of
treatment doses needed to treat a proportion of the infected population. In developing the
simulation of an infected population, we used an individual simulation model calibrated with
data from Kenya. We showed that coverage is not a static concept, and the conventional
way of thinking about coverage is not sufficient to describe the effect of treatment on the
population. This fact is a direct consequence of the treatment effect on patients’ lives.
We introduced cumulative incidence-based coverage as the long run proportion of infected
patients who receive treatment in their life time. We showed that this new definition is
capable of capturing the effect of population growth on the resources needed to treat the
population. Our results show that to reach the goal of international organizations of covering
most of infected patients in Sub-Saharan Africa, we need substantially more resources than
what have been predicted.
For resource-limited settings, WHO guidelines recommend treating the sickest patients
in the population and treating them until death. HIV-infected patients who are on treatment
develop resistant mutations and treatment is marginally effective for them. Treating patients
until death hinders the opportunity of reallocating treatment to other patients who might
benefit more. In Chapter 4, we quantified the price of following the nonabandonment policies
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in HIV treatment in resource-limited settings. We proposed a mathematical model to find
efficient allocation of scarce HIV treatment for a broad class of admissible policies. Then, for
quantifying the price of nonabandonment policies we restricted our attention to two classes
of admissible policies: (i) nonabandonment, and (ii) abandonment-permitted. Solving the
allocation problem for each class of admissible policy is intractable since the state space
is unbounded. Therefore, we estimated a lower bound on the price of nonabandonment
policies by the difference between a lower bound on the performance in the abandonment-
permitted setting and an upper bound of that for the nonabandonment setting. For finding
the lower bound we provided an algorithmic approach based on the linear programming
approach to approximate dynamic programming. We showed that the optimal policy of
the approximation problem is state-dependent priority-rule. We provided two techniques to
compute the upper bound. The first one is based on the relaxation of our problem and the
second one is a natural bound from ADP. By providing upper bounds for our approximations
we showed that the policies produced by our algorithmic approach are near optimal. Our
results show that the price of nonabandonment policies is as much as 41% of the total
discounted QALYs of the whole population. We also analyzed the optimal ADP policy
to derive insights on how they assign treatment and remove patients from treatment in a
variety of settings. Our results show that both risk and health are important in assigning
treatment. In particular, risk is relatively more important than health. The ADP policies
prioritize polygamous patients, then monogamous and finally children in assigning treatment.
Moreover, the ADP policies prioritize patients with moderate health state in most scenarios.
In removing patients from treatment, the ADP policies remove patients from treatment
when the maximum CD4 count reaches the best health category. By removing patients from
treatment a larger proportion of the infected population can be treated, resulting in more
QALYs for the whole population. We used the large-scale HIV simulation model to test
the performance of allocation policies. Our results show that the ADP policies outperform
WHO recommendations by as much as 8%.
When to start HIV treatment is a fundamental question in the HIV literature. Available
models assume a fixed number of available treatment doses and do not consider the rate
of new antiretroviral development on optimal timing of HIV treatment. In Chapter 5, we
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investigated the effect of pipeline drugs on HIV treatment in resource-rich settings. We used
a split Poisson process to model the arrival of HIV pipeline drugs. Then, we used data
on pipeline drugs approved by the Food and Drug Administration to calibrate our model.
We incorporated the arrival of HIV pipeline drugs into the validated HIV simulation model
to analyze the effect of pipeline drugs on: (i) the optimal time to initiate treatment, and
(ii) QALYs of patients. Our model with the inclusion of pipeline drugs supports earlier
treatment strategies. In particular, it supports initiating HIV treatment at the CD4 count
of 500 cells/mm3. Our results show that considering pipeline drugs can increase the QALYs
of patients by as much as 8%. Moreover, our sensitivity analysis shows that reducing the
toxicity of pipeline drugs can increase the QALYs of patients by 13%. Therefore, for designing
new antiretroviral drugs, reducing the toxicity should be the first priority.
Limitations of this work lie both on modeling assumptions and data. For instance, in
Chapter 3, we assumed that the rate of new infections to the population is constant and
independent of treatment. It is well established in the HIV literature that treatment reduces
infectivity by reducing the viral load of patients. We will consider the effect of treatment
on transmission in the future work. In Chapter 4, we assumed that policy makers have
constant treatment doses at the beginning of each period. However, in Sub-Saharan Africa
the number of treatment doses has increased during the past decade. We plan to extend
our model to consider a dynamic environment where resources are a function of time. A
primary data challenge in Chapter 4 is to find the probability that an individual changes his
risk category in a period. In addition, the distribution over the risk groups is not known.
While some assumptions and data are not comprehensive enough to solve our models, they
provide a methodological framework for insights into these vexing questions.
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